Paediatric oral biopharmaceutics : key considerations and current challenges by Batchelor, Hannah K. et al.
1 
 
Title: Paediatric oral biopharmaceutics: key considerations and current challenges 
• Author names and affiliations.  
Hannah K Batchelor1, Nikoletta Fotaki2 and Sandra Klein3 
Dr Hannah Batchelor (corresponding author) 
1Pharmacy, Pharmacology and Therapeutics Section, School of Clinical and Experimental Medicine, College of 
Medical and Dental Sciences, Medical School Building, University of Birmingham, Edgbaston B15 2TT, United 
Kingdom 
Tel: +44(0)121 4143717 
Email: h.k.batchelor@bham.ac.uk  
    
Dr Nikoletta Fotaki  
2Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, United 
Kingdom  
Tel: +44(0)1225 386728  
E-mail: n.fotaki@bath.ac.uk 
 
Prof. Dr. Sandra Klein 
3Ernst Moritz Arndt University Greifswald, Department of Pharmacy, Institute of Biopharmaceutics and 
Pharmaceutical Technology, Center of Drug Absorption and Transport, Felix-Hausdorff-Strasse 3  
17489 Greifswald, Germany 
Phone: ++49 (0) 3834 86 4897 
E-mail: Sandra.Klein@uni-greifswald.de  
 
 
 
  
2 
 
Abstract  
 
The complex process of oral drug absorption is influenced by a host of drug and formulation properties as well as 
their interaction with the gastrointestinal environment in terms of drug solubility, dissolution, permeability and pre-
systemic metabolism. For adult dosage forms the use of biopharmaceutical tools to aid in the design and 
development of medicinal products is well documented. This review considers current literature evidence to guide 
development of bespoke paediatric biopharmaceutics tools and reviews current understanding surrounding 
extrapolation of adult methodology into a paediatric population. Clinical testing and the use of in silico models 
were also reviewed. The results demonstrate that further work is required to adequately characterise the 
paediatric gastrointestinal tract to ensure that biopharmaceutics tools are appropriate to predict performance 
within this population. The most vulnerable group was found to be neonates and infants up to 6 months where 
differences from adults were greatest. 
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 General Introduction 
Biopharmaceutical science is used widely within drug development to predict in vivo performance of 
a medicine. The use of biopharmaceutical science within paediatric formulation development is 
limited and has previously been highlighted as an area where additional research is required [1, 2]. 
Prediction of in vivo performance of medicines requires knowledge regarding the physiology and 
anatomy of the site of drug absorption. Although many differences will be highlighted within this 
review the differences in the gastrointestinal physiology and anatomy of paediatric populations 
compared to adults has been the subject of some excellent reviews and the reader is directed to 
these papers for a full discussion [3-5].  
This review is limited to a discussion of oral biopharmaceutics and the factors that affect differences 
in absorption in paediatric populations compared to adults. Information is presented to best direct 
in vitro and in silico testing of paediatric medicines. 
 
 Paediatric Biopharmaceutics – Current Regulatory Guidance Status 
There has been global emphasis on improving paediatric accessibility to medicines which has 
increased the number of drugs tested in and labelled for use in children. For example, the United 
States (US) Food and Drug Administration’s (FDA) paediatric labelling database has 467 reports on 
paediatric clinical studies listed in response to paediatric legislative changes [6]. There are existing 
reviews detailing overarching paediatric medicines regulations in the US and Europe (eg [7, 8]). 
Paediatric labelling of medicines was introduced in 1979 in the USA [8], since that date there have 
been significant changes in regulations regarding paediatric medicines.  Very recent (2013) FDA draft 
guidance [9] on information to be contained in paediatric labelling does not include any details on 
the nature of tests to be conducted or link to any biopharmaceutics guidance. This review details 
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regulatory guidance relating directly to biopharmaceutics and how this is managed for paediatric 
populations compared to adults.  
2.1. Extrapolation of adult pharmacokinetic data into paediatric populations 
US regulatory guidance on exposure-response relationships [10] includes a “Pediatric Study Decision 
Tree” (Figure 1) which justifies extrapolation from adult data into paediatric populations in cases 
where the course of the disease and effect of the drug are sufficiently similar in adults and paediatric 
patients. However, it is important to note that this extrapolation refers only to efficacy, not to safety 
or dose adjustments.  
Paediatric regulation within Europe has tended to follow US regulation. Similar to the US paediatric 
decision tree, ICH E11 guidance states that, “When a medicinal product is to be used in the pediatric 
population for the same indication(s) as those studied and approved in adults, the disease process is 
similar in adults and pediatric patients, and the outcome of therapy is likely to be comparable, 
extrapolation from adult efficacy data may be appropriate” [11]. The guidance also proposes 
extrapolation from older to younger paediatric patients where the disease process is similar. 
The EMA concept paper on extrapolation goes further than existing documents driving towards a 
refined algorithm that considers clinical aspects where any form of extrapolation needs to be 
justified together with an explicit hypothesis on the expected difference in response to a medicine 
between the target population and the source population [12]. 
However, when adult data have been used to predict performance in paediatric populations there 
are examples of unexplained and sometimes adverse events (eg [13-15]). A commonly cited example 
is the administration of chloramphenicol to neonates at doses that were extrapolated from those 
found effective and safe in adult patients which resulted in grey baby syndrome. These children 
exhibited emesis, abdominal distension, abnormal respiration, cyanosis, cardiovascular collapse and 
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death. A difference in metabolism and clearance in neonates relating to an immature UDP 
glucuronosyl transferase system were subsequently demonstrated to be responsible [16]. 
 
2.2. Biopharmaceutics-specific regulatory guidance 
Biopharmaceutics guidance from the US includes information on the conduct of dissolution testing 
for in vitro in vivo correlations; the application of the biopharmaceutics classification system (BCS) to 
justify a biowaiver, food effect studies and bioequivalence studies. European Medicines Agency 
(EMA) provides biopharmaceutics guidance on similar topics: bioequivalence testing; BCS based 
biowaivers; the role of pharmacokinetics in the development of medicinal product in the paediatric 
population. These documents are reviewed in terms of paediatric applicability within Table 1. 
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Table 1. Applicability of existing biopharmaceutics regulatory guidance to paediatric formulation 
development 
Guidance 
Document/Topic 
Source 
and Date 
Current applicability to 
paediatric populations 
Clarification required 
Dissolution Testing 
 
   
Dissolution testing 
guidance for IR solid 
dosage forms 
FDA 
1997 
[17] 
No mention of “pediatric” or 
“child” within existing 
guidance. 
 
BCS based classifications are used to 
determine testing schedule yet the 
dose:solubility ratio fundamental to BCS 
classification cannot be directly 
extrapolated into paediatric populations 
The volume within the dissolution test 
(>500mL) is unlikely to be appropriate for 
the full range of paediatric patients 
 
Extended Release 
Oral Dosage Forms: 
Development, 
Evaluation, and 
Application of In 
vitro in vivo 
correlations 
 
FDA 
1997 
[18] 
No mention of “pediatric” or 
“child” within existing 
guidance. 
 
All in vitro data refers to correlations with 
adult in vivo performance  
Existing in vitro testing (dissolution) is 
based on historic relevance for adult 
populations (volume, pH etc) 
BCS Guidance 
 
   
Waiver of in vivo 
Bioavailability and 
Bioequivalence 
Studies for 
Immediate-Release 
Solid Oral Dosage 
Forms Based on a 
Biopharmaceutics 
Classification System 
 
FDA 
2000 
[19] 
 
No mention of “pediatric” or 
“child” within existing 
guidance. 
 
A drug substance is 
considered highly soluble 
when the highest dose 
strength is soluble in 250 ml 
or less of aqueous media over 
the pH range of 1-7.5. 250 ml 
is derived from typical BE 
study protocols that prescribe 
administration of a drug 
product to fasting adult 
volunteers with a glass of 
water. 
  
 
Revised paediatric BCS classifications are 
required to account for reduced volume of 
liquid taken with dosage form 
Proposal to waive in 
vivo bioequivalence 
requirements for 
WHO Model List of 
Essential Medicines 
immediate-release, 
solid oral dosage 
forms 
WHO 
2006 
No mention of “paediatric” or 
“child” within existing 
guidance. 
 
BCS high solubility definition 
amended to dose:solubility 
ratio of 250mL or lower over a 
pH range of 1.2-6.8 
Refers to the highest dose, 
rather than highest dose 
Revised paediatric BCS classifications are 
required to account for reduced volume of 
liquid taken with dosage form 
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strength 
    
Clinical Studies 
Guidance 
 
   
Food-Effect 
Bioavailability and 
Fed Bioequivalence 
Studies 
FDA 
2002 
[20]  
No mention of “pediatric” or 
“child” within existing 
guidance. 
Sponsors may choose to 
conduct additional studies for 
a better understanding of the 
drug product and to provide 
optimal labelling statements 
for dosage and administration 
(eg different meals and 
different times of drug intake 
in relation to meals). 
Subjects should be healthy 
volunteers drawn from the 
general population 
Highest dose strength should 
be tested 
Meal of 800-1000 calories to 
be used 
Medicine taken with 240mL 
water 
Sprinkle formulations should 
be tested using the food listed 
in the product labelling (eg 
applesauce) 
Special beverages as vehicles 
– these should also be tested 
as per the labelling 
 
Appropriate standardised meals 
representative of paediatric populations 
are required to ensure testing is adequate 
Bioavailability and 
Bioequivalence 
Studies for Orally 
Administered Drug 
Products – general 
considerations 
FDA 
2003 
[21] 
No mention of “pediatric” or 
“child” within existing 
guidance. 
Clinical study should be 
conducted in a representative 
population by age, sex and 
race. Yet recommendation 
that subjects should be over 
18. 
Bioequivalence between formulations is 
currently tested in adults with 
extrapolation of paediatric. However, 
paediatric physiology may influence 
formulation performance thus 
appropriate testing should be 
recommended 
Guideline on the 
Investigation of 
Bioequivalence 
EMA 
2010 
[22] 
Healthy volunteers stated to 
provide adequate for 
extrapolation of results into 
children 
Medicinal product to be taken 
with >150mL water 
For fed studies: 
Meal of 800-1000 calories to 
be used 
 
 
Guideline on the role 
of pharmacokinetics 
in the development 
of medicinal 
EMA 
2006 
[23] 
No mention of 
biopharmaceutics – guidance 
on study design rather than 
biopharmaceutical testing 
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products in the 
paediatric 
population 
strategies 
Draft guideline on 
pharmaceutical 
development of 
medicines for 
paediatric use 
 
 
EMA 
2013 
Rev. 1 
[24] 
Identifies key issues in 
formulation design with 
relevance to 
biopharmaceutics including: 
managing formulation 
changes; the impact of 
manipulation with food and 
drink; the impact of 
physiology on performance of 
modified release dosage 
forms 
No details are provided on the tools or 
appropriate testing strategies to 
understand issues highlighted. 
Clinical Investigation 
of Medicinal 
Products in the 
Paediatric 
Population 
EMA/ICH 
E11 2001 
[11] 
Relevant safety data for 
paediatric studies ordinarily 
come from adult human 
exposure with extrapolation 
for efficacy 
Relative bioavailability of the 
paediatric formulation with 
the adult oral formulation 
should typically be conducted 
in adults 
Definitive PK studies should 
be done in paediatric 
populations 
Knowledge of clearance 
pathways (renal and 
metabolic) and understanding 
age related changes of these 
processes aids in planning 
paediatric studies 
Specific age related changes 
in pre-term neonates are 
discussed 
 
Guideline on the 
investigation of 
medicinal products 
in the term and 
preterm neonate  
EMA and 
PDCO 
2009 
[25] 
Identifies key issues including: 
a need for specific 
formulations; understanding 
(from literature) of ontogeny 
of metabolising enzymes; 
changes in bioavailability due 
to maturational changes 
within the GI tract need to be 
considered and predicted. 
Relevant safety data should 
come from adults or older 
children prior to testing in 
neonates where possible. In 
vitro data that predicts the in 
vivo situation should be used. 
Population PK approaches are 
recommended for PK studies. 
Relative bioavailability studies 
for specific formulations 
should be conducted in adults 
or older children where 
Very limited data presented on 
appropriate tools to use for in vitro testing 
to predict in vivo performance 
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possible 
Guideline on the 
investigation of drug 
interactions 
EMA/ICH 
2012 
[26] 
Drug-drug interactions in 
paediatric populations need 
to be considered with specific 
clinical studies within 
paediatric populations if 
appropriate. 
The use of sparse PK sampling 
or simulation is 
recommended to understand 
paediatric populations 
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A key step forwards in paediatric biopharmaceutics was the release of draft guidelines on 
pharmaceutical development for paediatric use released by the EMA [24]. This document highlights 
the need for appropriate testing to support formulation changes during development of a paediatric 
formulation; the importance of changes in bioavailability when extemporaneously manipulating a 
solid dosage form by mixing with food or drinks; the impact of physiology on the absorption of drugs 
administered as modified release formulations. However the guidance does not provide details on 
how these aspects should be measured and whether in vitro testing may be used to minimise the 
number of clinical studies conducted. 
As biopharmaceutical testing is designed to mimic in vivo performance of medicines, it is essential 
that appropriate regulatory guidance is available to support the design and development of 
paediatric medicines to enable rational design of appropriate clinical testing. 
 
 Solubility 
Intestinal absorption of drugs following oral administration is a function of drug dissolution and 
subsequent permeation and/or transport of the dissolved compound through the mucosa at the 
absorptive sites in the gastrointestinal (GI) tract. Since only dissolved drugs can be absorbed to a 
relevant extent, the solubility of the compound in the intraluminal fluids/contents is an essential 
prerequisite for its oral bioavailability. 
In general, the solubility of a drug depends on the physical and chemical properties of the solute and 
the solvent as well as on temperature, pressure and the pH of the solution [27]. The solubility of a 
drug is, to a large extent, due to the polarity of the solvent, which, in GI fluids, is typically 
represented by an aqueous environment. Moreover, ionised compounds exhibit greater aqueous 
solubility than their unionised counterparts. Media pH and buffer capacity exhibit a huge impact on 
drug ionisation (where relevant), which , in turn, can strongly affect the aqueous solubility of such 
compounds [28]. As a result, the solubility of weak bases is typically lower at higher pH values where 
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the drug is largely present in the unionised form. Solubility of a compound in the GI contents can be 
affected by additional parameters, for example the fat content of the GI contents or micelle 
formation. For soluble drugs, most of these parameters play a subordinate role. However, they can 
be crucial for limiting the intraluminal solubility of poorly soluble and/or ionisable drugs. Thus, to 
predict the in vivo solubility based on in vitro data, it is important to adequately address the relevant 
parameters of intraluminal fluids within solubility measurements. In the scientific literature, various 
approaches are described for determining the solubility of a drug compound. However, the 
relevance of these approaches for estimating the solubility of a given compound in GI conditions of 
the paediatric population is questionable. 
3.1. Compendial solubility methodology 
The solubility of a drug can be expressed in several ways. European Pharmacopoeia (Ph.Eur.) [29] 
and United States Pharmacopoeia / National Formulary (USP/NF) [30] define the solubility as parts 
of solvent required for one part of solute, as listed in Table 2. 
Table 2: Compendial solubility definitions [29, 30] 
Descriptive Term 
Parts of solvent required for one 
part of solute 
Very soluble Less than 1 part 
Freely soluble 1 to 10 parts 
Soluble 10 to 30 parts 
Sparingly soluble 30 to 100 parts 
Slightly soluble 100 to 1000 parts 
Very slightly soluble 1000 to 1000 parts 
Practically insoluble More than 10000 parts 
Compendial solubility experiments are typically performed at ambient temperature (15-25°C) where 
typical solvents comprise mainly water, different alcohols, acetone, methylene chloride and fatty oils 
and pH values are not addressed.  
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Ph. Eur. and USP/NF approaches to solubility measurements, where solubility experiments in a series 
of aqueous media of different pH are conducted, provide only a coarse estimate of the solubility in 
such conditions rather than resulting in any quantitative information on the in vivo solubility of the 
compound.  
3.2. BCS solubility approach and Dose:Solubility ratio 
The Biopharmaceutics Classification System (BCS) established by Amidon et al.. (1995) [31] is 
regarded as one of the most significant prognostic tools for estimating the in vivo bioequivalence of 
orally administered formulations. It is based on a scientific framework describing the major rate 
limiting steps in oral drug absorption. These are (i) the solubility of the active compound in GI pH 
conditions, (ii) the intestinal permeability characteristics of the active and (iii) its release (dissolution) 
from the final dosage form. This information is assumed to be a surrogate for the in vivo 
performance of oral immediate release (IR) formulations.  
Solubility determination according to the BCS is essentially different from the pharmacopoeial 
approach. The main principle is to determine the compounds´ solubility at 37°C over the entire GI pH 
range of pH 1 to 6.8 [32] or 7.5 [19], respectively. In addition, the BCS takes into account the highest 
dosage strength that will be administered to the patient as a single dose. Instead of indicating the 
solvent:solute ratio or the drug solubility in mg/mL solvent, the dose:solubility ratio (D:S) is 
calculated for at least three pH conditions (pH 1, 4.5, 6.8 or 7.5) taking into account the highest 
single dose and the experimental solubility values obtained at 37 °C in at least three media. A drug 
substance is classified as highly soluble when the D:S ratio is equal or less than 250 mL in all pH 
conditions. This amount is a conservative estimate of the fluid volume available in the GI tract under 
fasting-state conditions and is based on the volume usually administered with the dosage form (the 
so-called FDA glass of water) in a bioequivalence (BE) study [33]. However, at this point, it should be 
kept in mind that both the highest dosage strength assumed for the calculations, as well as the 
volume of 250 mL are valid for adults and cannot simply be extrapolated to the paediatric 
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population. Moreover, a paediatric BE standard has not been established [1], i.e. there is no 
standardized volume that could be referred to when calculating a D:S ratio. The potential design 
parameters for a paediatric BCS (PBCS) system have been discussed recently [1, 2]. However, based 
on the data currently available, it was not possible to decide on a volume that could be used to 
calculate a meaningful D:S in a paediatric population [1, 2]. However, even with these critical 
knowledge gaps, it is clear that a meaningful PBCS needs to be broken down into several different 
age groups that account for developmental changes in intestinal permeability, luminal contents, and 
gastrointestinal (GI) transit [1]. In contrast, it is unlikely that a simple and empiric approach 
translating the intraluminal fluid available into a volume assumed to be available for dissolution in 
the paediatric GI tract by simply using 1/10 of the volume used to simulate the volume available in 
the adult GI tract ( 25 mL), as tentatively proposed by Amidon [1], will provide meaningful 
solubility results for children of different age categories. Even with the little data available to date, as 
a result of dynamic developmental physiology of children, there is most likely no linear relationship 
between the fluid volumes available in the gastrointestinal tract. Moreover, the pH-conditions in the 
different GI sections can be significantly different from those in adults. This is particularly true for 
the first 2 to-5 years of age (Table 4) and will make a universal PBCS approach impossible. 
Nevertheless, establishing a PBCS would be very helpful in the different stages of paediatric 
formulation development. In order to develop an in vivo predictive solubility test for paediatric 
populations, beside the pH and the volume available for drug dissolution, many additional 
parameters that can affect the solubility of a compound in intraluminal conditions, for example the 
presence of bile salts and digestive products will need to be addressed. 
3.3. Biorelevant solubility approach 
Several researchers have focused on developing test conditions that reflect the intraluminal 
conditions in the fasted and fed state upper GI tract as typically IR formulations release the drug in 
this area. The impact of different dosing conditions (fasted versus fed-state administration of a 
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dosage form) and consequences on GI physiology are also expected to occur at this site have also 
been considered. As a result, a series of biorelevant media to simulate conditions in the adult 
stomach and small intestine before and after meals have been introduced  which are detailed in 
Table 3 [34]. 
Table 3: Biorelevant media used to simulate upper GI conditions in adults 
Medium GI section Prandial status Relevant parameters Reference 
FaSSGF  
pH 1.6 
Stomach Fasted  pH 
 surface tension 
 osmolality 
[35] 
FeSSGF  
pH 5.0 
Stomach Fed  pH 
 surface tension 
 osmolality 
[36] 
Milk Stomach Fed - immediately 
after a light 
breakfast 
 pH 
 surface tension 
 fat:protein:carbohydrate 
ratio 
[37] 
Ensure Plus Stomach Fed - immediately 
after a standardized 
high fat breakfast 
(FDA Standard 
Breakfast) 
 pH 
 fat:protein:carbohydrate 
ratio 
 surface tension 
 osmolality 
[38] 
FaSSIF  
pH 6.5 
Small intestine Fasted  pH 
 surface tension 
 osmolality 
 bile salt concentration 
[39] 
FaSSIF-V2  
pH 6.5 
Small intestine Fasted  pH 
 surface tension 
 osmolality 
 bile salt concentration 
[36] 
FeSSIF  
pH 5.0 
Small intestine Fed  pH 
 surface tension 
 osmolality 
 bile salt concentration 
[39] 
FeSSIF-V2  Small intestine Fed  pH [36] 
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pH 5.8  surface tension 
 osmolality 
 bile salt concentration 
 digestive products 
Since their introduction, these biorelevant media have been successfully used in both solubility and 
dissolution experiments. Based on novel scientific findings in the recent past, some of these media 
were updated (Version 2 (V2)) to even more closely represent both the pre- and postprandial states 
in the upper GI tract [35, 36]. Particularly, Fed State Simulating Small Intestinal Fluid (FeSSIF) has 
undergone a significant revision. Besides the bile components sodium taurocholate and lecithin, the 
updated medium also contains digestive products, i.e. glyceryl monooleate and sodium oleate, that 
may contribute to the solubilisation of a drug [34]. With existing biorelevant media, it is possible to 
simulate different adult in vivo pH scenarios by selecting media appropriate to typical dosing 
conditions in clinical studies [20], as well as addressing various additional physicochemical 
parameters, for example, the osmolality, surface tension, bile salt concentration and the presence or 
absence of digestion products, that are expected to affect drug solubility in the GI tract of an 
average adult. However, as already mentioned, these media were developed on the basis of human 
adult physiology and do not necessarily represent the relevant conditions in the paediatric GI tract.  
3.4. Biorelevant solubility approach for paediatric populations 
Since the physiological conditions in the GI tract of children, associated with growth and maturation, 
can significantly differ from that in adults, neither compendial, BCS solubility approaches, nor the 
current set of biorelevant media are applicable to estimate a drugs´ in vivo solubility in the GI tract 
of a child. This will be particularly true for very young infants and children, where the developmental 
effects on GI physiology are reported to be most pronounced [3, 4, 40]. 
In paediatric drug therapy, currently many drugs are administered in the form of solutions, syrups, 
suspensions, thin strips or orally disintegrating granules and tablets. In contrast to most of the adult 
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dosage forms which are solids that are swallowed whole and where the first important site for drug 
dissolution is typically the stomach. Paediatric formulations are often designed to be retained in the 
oral cavity. Residence in the oral cavity might have an impact on the bioavailability of certain drugs 
and thus, the fluid composition in the oral cavity should be considered in a biorelevant paediatric 
solubility approach. This may be of significance for poorly soluble weakly basic drugs that are likely 
to precipitate in more neutral pH-conditions [41] typically found within the oral cavity. An example is 
the weak base itraconazole which is used in the treatment of invasive fungal infections in children 
and is often administered as oral solution [42]. The neutral pH conditions in the oral cavity can also 
result in a loss of integrity of sensitive enteric coatings of tablet or granule formulations, if the 
dosage form is not immediately swallowed but kept in the mouth longer than anticipated for the 
formulation design. Similar to the biorelevant solubility approach for adults, a truly meaningful 
solubility approach for paediatrics should take into account the physicochemical properties, the 
overall composition of oral, gastric and small intestinal fluids including pancreatic and bile secretion 
and the available fluid volumes in the fasted state and in response to a typical age-related meal. It 
clearly becomes obvious that such an approach requires a lot of detailed information on (i) the 
dosing conditions, including the typical maximum dose; (ii) the typical volume of fluid co-
administered with the dosage form and (iii) the average size and composition of typical meals for 
each age category. Only with this information, is it possible to calculate a BCS-like and/or biorelevant 
solubility for paediatric patients that represents the oral cavity. 
Based on these considerations, a universal solubility approach for the paediatric population is rather 
unlikely. Even, if the most significant differences in fluid composition between adults and children 
are likely to be seen in very young children, one needs to consider that the dimensions of the 
gastrointestinal tract continuously change throughout childhood and adolescence. This maturation 
process will affect the capacities of the oral cavity and the different GI sections and thus the volume 
available for dissolution, resulting from the resting volumes of fluid, the volume that can be co-
administered with an oral dosage form and gastrointestinal secretions. 
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Even if the volume available for dissolution was available for each age group, a simple adaption of 
the classical BCS solubility approach to children is unlikely to provide the intended in vivo 
predictivity, since the impact of various components of the physiological fluids, for example, the 
presence of bile compounds and digestion products which are often essential for the solubilisation 
of drugs in lumen of the small intestine [34], are not taken into account. Depending on the 
properties of the drug, a fine-tuned, but still classical BCS-like approach is thus unlikely to result in 
prediction of the in vivo solubility in the paediatric GI tract. However, at this point, it should also be 
kept in mind that the BCS was never established with the objective to obtain an in vitro / in vivo 
correlation. 
In response to the new European Union regulations on children´s medicines, recently, several 
attempts have been made to review literature data on the GI physiology with respect to parameters 
that could affect drug absorption in paediatrics and to highlight the similarities and differences 
between adult and paediatric populations [4]. As expected, due to ethical reasons associated with 
performing invasive tests in healthy children, knowledge of the physiological changes that occur 
along the GI tract in response to growth and maturation is incomplete [1, 4]. Several attempts have 
been made in reviewing and summarizing the most relevant changes in fluid composition and 
volumes in the upper GI tract (Table 4). However, although the intention of these reviews was to 
summarize and discuss the parameters of paediatric gastrointestinal physiology relevant to oral drug 
delivery, it is obvious that the data currently available are insufficient for designing biorelevant 
solubility tests for the various paediatric age groups. It is also notable that the most significant 
differences to adult GI physiology are found in newborns and infants, whereas as early as in pre-
school children the oral, gastric and small intestinal fluid compositions seem to be very close to that 
of adults. However, caution is required with the data presented as the cited review articles only 
report average values of physiological parameters, and statistical parameters (number of subjects, 
minimum/maximum values, and standard deviations) are not mentioned. The typical fluid volumes 
available at the relevant sites in the paediatric GI tract are also not discussed. It should be further 
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noted, that the stated physiological values in children vary greatly within the literature [4]. Many of 
the reported studies were performed in a small number of subjects which were not necessarily 
healthy children, but often suffered from a particular disease. For example, Kaye et al.. (2011) 
reported average gastric pH values in infants that resulted from a study involving five Helicobacter 
pylori-infected and five uninfected children [43]. Many of the cited values also result from cross-
referencing [3] rather than from a systematic study of the original literature. Several of the data, eg 
the stomach capacity [4] are reported from textbooks which are more than 15 years old. This 
indicates that the data might not necessarily represent what is needed for developing a biorelevant 
test. Overall, most of the reviewed studies did not follow the same or regulatory age classifications 
making comparisons difficult, as they were designed to measure particular parameters in diseased 
children and covered a broad range of ages. As also concluded by Abdel-Rahman et al. (2012) and 
Batchelor et al. (2013) [1, 2], at the moment there are significant knowledge gaps that will hinder 
the development of age-specific biorelevant solubility tests for children. 
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Table 4: Average age dependent physiological factors that may influence in vivo solubility, dissolution of oral dosage forms and subsequent drug absorption 
as reported in recent overview/review articles on paediatric physiology [1, 3, 44, 45]. 
Parameter Newborn 
(0-28d) 
Infant 
(1m-2 years) 
Child  
(2-5y) 
Child  
(6-11y) 
Adolescent  
(12-18y) 
Saliva pH 7 [4]  7.1 [4] 7.1 [4] 7.4 [4] 
Gastric fluid pH at birth pH is close to 
neutral (pH 6-8);  
significant acid 
secretion over the next 
24-48 h, resulting in a 
pH of 1-3.5; then 
gastric acid secretions 
declines and the pH 
increases to near 
neutral for 20-30 days 
before its starts to 
decrease again [4, 44] 
 
 
on a per kg basis, adult 
levels are approached 
by 2 years of age [3, 
44]; from about 3 
months of age [1, 4] 
 
 
 
 
 
 
 
 
1.4 [4] 
~ adult [44] [3, 4] 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 [4] 
~ adult [4] 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 [4] 
~ adult [4] 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 [4] 
Gastric emptying time reduced (variable) [44] 
[3] 
 
 
increased [3, 44]; 
delayed in children 
aged 6-8 months [3]; 
~ adult after 6 months 
~ adult [4] 
 
 
 
~ adult [4] 
 
 
 
~ adult [4]  
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54-82 min [4] 
of age [4] 
 
12-70 min [4] 
 
 
12-70 min [4] 
 
 
12-70 min [4] 
 
 
12-138 min [4] 
Gastric acid / pepsin 
output 
Relatively low [3, 44] ~ adult when calculated 
based on body weight 
[3, 44] 
~ adult [3, 44] ~ adult [3, 44] ~ adult [3, 44] 
Stomach capacity 10-100 mL [4] 90-500 mL [4] 750-960 mL [4] 750-960 mL [4] 1500 mL [4] 
Small intestinal pH   ~ adult [4] ~ adult [3, 4] ~ adult [3, 4] 
Intestinal transit time reduced [44]  
 
4 h [4] 
increased [44] 
 
4 h [4] 
 
 
3-7.5 h [4] 
 
 
3-7.5 h [4] 
 
 
3-7.5 h [4] 
Pancreatic / biliary 
function 
immature [3] ~ adult [3]    
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 Permeability 
Intestinal absorption of macronutrients (carbohydrates, fat and proteins) as well as ions and trace 
elements is essential for the growth of children. Maturation of the gastrointestinal tract is reported 
to occur within the first 6 months; therefore drugs absorbed by transport processes used for 
nutrients that are essential for growth may show different absorption profiles during the first 6 
months of life. Permeability of drugs within in paediatric populations is an under-researched area; 
this review focuses on permeability within the small intestine as this is the most important site in 
terms of oral biopharmaceutics. It is recognised that existing knowledge on developmental changes 
in the GI processes including transporter expression is very limited. 
 
4.1. Intestinal surface area and membrane permeability 
Contradictory evidence exists relating to the morphology of the small intestine during development, 
with reports of similar villus surface area in adults and infants [46] and villi that are narrower with 
smaller crypts in neonates  [47]. Since the length and diameter of the small intestine increases 
continuously from birth till adulthood, the functional surface area of the small intestine increases 
more than 40-fold [48].  
Intestinal permeability is reported to be high at birth and decreases progressively during the first 
week of life [49]. This may be related to the reduced surface area: volume ratio due to the villi being 
broader and providing a smaller overall surface area; this phenomenon is well documented in rats 
[50]. 
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4.2. Passive permeability 
The composition and fluidity of the intestinal membrane has been reported in change as a function 
of age; with a reduction in fluidity following the post-weaning period in rats attributed to an increase 
in the cholesterol:phospholipid molar ratio [51, 52].  
Sugar absorption tests are typically used to assess intestinal permeability as these are minimally 
invasive; following enteral administration of a test solution containing lactulose and mannitol, the 
excretion of these sugars is measured in urine. Testing typically involves two sugars as 
monosaccharides (eg mannitol) are readily absorbed via the transcellular pathway but larger 
disaccharides (eg lactulose) are absorbed through the paracellular pathway. Therefore the ratio of 
lactulose:mannitol (L:M) in the urine is a measure of intestinal integrity with decreases in the L:M 
ratio typically attributed to a decrease in L and an increase in M recoveries. Sugar absorption studies 
reported from paediatric populations are detailed in Table 5.   
Table 5. Sugar absorption tests conducted in paediatric populations 
Age Group Finding Comments Reference 
Preterm infants 
(25-32 weeks) 
L-Rhamnose used as monosaccharide 
showed decreased permeability with 
age 
Increased permeability of L with age 
Intestinal permeability (ratio L:R) 
increased with age 
 [53] 
Preterm infants 
(26-36 weeks) 
Intestinal permeability (ratio L:M) 
decreased with age within the first 
week following birth 
Values within a week 
of birth were similar to 
those in term neonates 
[49] 
Preterm compared 
to term neonates 
Intestinal permeability is higher in pre-
term infant compared to term 
 [54] 
Neonates within 1 
week of life 
Permeability of L decreased with age 
L:M ratio decreased with age 
Permeability of L 
reached mature values 
within weeks following 
birth 
[55] 
0.5 months -14 Intestinal permeability (ratio L:M)  [56] 
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years decreases with age 
Permeability of L does not change with 
age 
Permeability of M increases with age 
0-1 month Intestinal permeability (ratio L:M) 
decreased with age 
 
The food used in the 
first month of life 
affects the rate of 
decrease in 
paracellular 
permeability with 
breast fed infants 
demonstrating a more 
rapid decrease 
compared to formula 
fed babies 
[57] 
1m – 3 years Intestinal permeability (ratio L:M) is 
equivalent to adult values 
 [58] 
Abbreviations used in the table are: L = lactulose; M = mannitol and R = Rhamnose. 
The conclusion from the data in Table 5 is that the permeability of the membrane decreases with 
age yet the age at which adult values are reached is unclear; therefore dose adjustments in the very 
young need to be undertaken with caution as membrane permeability may be higher than predicted 
based on adult values. There is controversy within the literature with contradictions in the impact of 
age on the permeability of monosaccharides [53, 56]. The permeability of lactulose is reported to be 
unchanged [56], increase [53], and decrease [55] with age highlighting the discrepancies within the 
literature.  
4.3. Active transport permeability 
Nutrients and ions are generally absorbed by active transport processes in the intestine. Expression 
of these transport processes is in line with the needs of the growing child. Therefore, compounds 
that are absorbed by transport processes that are involved in the growth of children are likely to be 
absorbed better in children than in adults. For example, young children (2 months to 8 years), have 
been shown to absorb more ingested lead than adults, 40-50 % vs 10-15 %, respectively [59]. Binding 
of lead to receptors in the enterocyte that serve for active transport of iron and calcium may 
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account for active transport of lead. But similar to the passive diffusion of calcium at higher (>2 mM) 
intraluminal calcium concentrations, lead can be absorbed by means of passive diffusion. It has been 
suggested that the higher absorption of lead in children compared to adults involves also enhanced 
pinocytotic activity in early life [59].  
 
Heimann (1980) studied the enteral absorption of drugs in children with several drugs showing 
similar overall absorption with age yet a significant increase in the rate of absorption (Ka) with age 
from neonates and young babies (up to 150 days) compared to older children[60]. Drugs 
investigated included: D(+)xylose, which is absorbed by an active mechanism in the upper small 
intestine; L(+) arabinose which is absorbed by passive diffusion; sulphonamides, phenobarbitol, 
digoxin and -methyldigoxin all showing similar results [60]. These findings suggest that the rate of 
absorption is slower in neonates and children yet the amount absorbed is similar (matched by mass). 
A further study was conducted to measure the effects of intestinal motility on absorption using 
metoclopramide; the results showed an increase in absorption rate constant, Ka, in both young and 
older infants yet the ratio of Ka: age remained constant [60]. These results suggest that the reduced 
Ka observed was not solely due to longer transit times or reduced motility but other factors are also 
likely to be involved. 
 
4.4. PGP Expression in the gut wall 
 
The efflux transporter P-glycoprotein (P-gp), also known as multidrug resistance protein-1 (MDR1), is 
a member of the adenosine-5’-triphosphate binding cassette family of proteins and is responsible for 
cellular drug efflux, transporting substances from the intracellular to the extracellular 
compartments. P-gp is found within the cellular membranes of the gastrointestinal tract and can 
markedly affect the bioavailability of certain drugs, particularly those with low solubility. Previously 
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it has been reported that the variability in intestinal absorption for many drugs, when used in 
combination, is likely to be a direct result of the variability of P-gp expression within the GI tract [61]. 
Many drugs that are P-gp substrates are also substrates of other efflux transporters as well as 
absorptive transporters (e.g. anion or cation transporters) therefore the overall transport of such 
drugs are most likely to be affected by both expression of P-gp and the presence of additional P-gp 
substrates. 
Methods used to quantify expression of P-gp are complex due to the difficulties associated with 
isolation of integral membrane proteins. Proteomic approaches [62] were used to determine protein 
expression levels of trypsin-digested breast cancer resistance protein (BCRP) and multidrug 
resistance-associated protein 2 (MRP2) in tissue samples [63-65], although limitations of these 
methods included poor reproducibility of extraction and sample digestion. Purification and 
reconstitution into proteoliposomes is possible (eg [66]), but expensive and technically challenging. 
Tucker et al. (2012) recently used an immunochemistry approach to generate transporter protein 
standards for immunoquantification [67]. 
Van Kalken et al. (1992) demonstrated expression of MDR1/P-gp mRNA in the embryonic phase of 
human development. However, some differences were found between foetal and adult human 
tissue distribution; prenatal intestine did not show staining of the epithelium, yet MDR1-mRNA 
expression was observed in late specimens [68]. Mahmood et al. (2001) studied the ontogeny of P-
gp in mouse intestine, liver, and kidney. Intestinal P-gp expression was limited at birth and increased 
significantly with maturation. Annaert et al. (2010) measured drug transport in intestinal tissue to 
investigate P-gp modulated transport and showed that adult expression levels were reached at 
about 6 weeks in rats [69]. These animal models suggest that P-gp expression increased with age 
although there is limited information on the age at which adult expression is reached. 
There is conflicting evidence regarding the ontogeny of expression of P-gp in paediatric populations.  
Johnson and Thomson (2008) reported that the expression of P-gp appears to increase rapidly during 
26 
 
the first 3-6 months of life, reaching adult levels by approximately 2 years of life [70]; whereas 
Fakhoury et al. (2005) reported that P-gp expression in the intestine was not influenced by age with 
mature expression in neonates and infants [71]. 
  
4.5. Techniques to measure permeability and the impact of age 
Permeability may be assessed by a variety of techniques including those based on in silico drug 
properties such as logD or hydrogen binding potential; in vitro passive diffusion across a membrane 
or cultured cell line or excised human or animal tissue; or in situ perfusion techniques. Typically 
simpler methods are used in the first instance with cut offs in terms of high and low permeability 
measured by comparison to drugs where in vivo fraction absorbed in known. There is specific 
guidance for formal BCS classification of high permeability [19]. All human perfusion data have been 
conducted in adult populations [72] and to date there have been no attempts to correlate these 
values of paediatric measures of permeability. 
Caco-2 cell lines are the most commonly used cell lines to measure permeability as they are high 
throughput and acceptable methods for BCS classification. However, these cell lines are known to 
underestimate true permeability due to (i) under-/over-expression of Pgp efflux pumps; (ii) reduced 
paracellular transport due to the absence of lipid pores; (iii) non-specific binding to components 
within the apparatus and (iv) high laboratory variability in the characteristics of Caco-2 cell cultures 
used, depending on passage used and growth media [73]. MDCK cells (of canine origin) are 
sometimes used as an alternative to Caco-2 cell lines as they form a monolayer in a shorter time 
period [74]; however the expression of various efflux pumps are low in this cell line. Double 
transfected MDCK cells where the canine transporters are replaced by human transporters are often 
used to better understand the influence of transporters on drug permeability (e.g. [75]). 
Due to very limited availability of human intestinal tissue for investigating intestinal drug transport, 
in vitro and ex vivo mechanistic studies on intestinal drug permeability have typically been 
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conducted in intestinal tissue obtained from animals. In rats microvascular permeability of a dye was 
reported to increase more than twofold from weaned to adult animals with a further increase 
observed in aged rats [76]. 
Annaert et al. (2010) measured the permeability of several drugs across excised rat intestinal tissue 
from 6 week old (young) animals compared to adult rats (14 weeks) using an Ussing chamber [69]. 
Metoprolol was used to assess transcellular transport with values similar in the young and adult rats; 
atenolol was used to assess paracellular transport and showed a decrease in permeability in adults 
compared to young rats; talinolol was used to assess P-gp modulated transcellular transport also 
showed a decrease in permeability in adult rats compared to young animals [69]. Additional studies 
were undertaken to better understand the impact of age on P-gp transport using verapamil in 
addition to talinolol; in adult rats the presence of verapamil significantly decreased the permeability 
of talinolol whereas the permeability was unaffected in young rats. This finding indicates that P-gp 
has a very limited role in the absorption of talinolol in the young animals [69].  
Said et al. (1990) measured the transport of biotin across intestinal tissue in rats comparing suckling, 
weaning and adult rats with significant decreased in permeability associated with age grouping; this 
finding was attributed to a decrease in the number of biotin transport carriers with age [77]. 
Garcia-Miranda et al. (2005) measured L-carnitine uptake across intestinal tissue from foetal, 
newborn, weaning, suckling and adult rats; high uptake was observed in foetal and newborn rats 
with a decrease during the suckling period to unmeasurable levels following weaning [78]. 
Carnitine/organic cation transporter (OCTN2) is the carrier system involved in apical L-carnitine 
uptake in the gut; Garcia-Miranda et al. (2005) measured OCTN2 mRNA from rat intestinal samples 
and the results matched those observed for transport with expression peaking in foetuses and 
newborn rats with a subsequent decrease with age [78]. 
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Folate absorption from the small intestine is mediated via the reduced-folate carrier (RFC). 
Balamurugan and Said (2003) measured folic acid uptake across brush border membrane vesicles 
isolated from suckling, weanling and adult rats; they reported a significant decrease in uptake with 
age [79]. Quantification of RFC protein and mRNA levels demonstrated significantly higher levels in 
suckling compared with weanling rats, which were in turn significantly higher than that in adult rats. 
4.6. Permeability within the oral cavity 
As stated in section 3.4 (Biorelevant solubility approach for paediatric populations) formulations 
used in paediatric populations are often retained within the oral cavity for longer than comparative 
adult preparations. Absorption within the oral cavity offers a means to bypass first-pass metabolism 
and avoid of pre-systemic elimination within the GI tract; however the relatively small surface area 
of the oral mucosa and the significant loss of drug due to uncontrolled swallowing and salivary flow 
are the main limitations of this route.  There is no literature evidence that details differences in 
permeability with age in buccal tissues. However, clinical data is available to demonstrate absorption 
of tacrolimus and midazolam via the oral cavity in paediatric patients [80, 81]. 
4.7. Developing paediatric permeability methods  
The lack of high quality paediatric pharmacokinetic studies reported limits knowledge regarding 
permeability mechanisms within this population. The few bioavailability studies that have examined 
the absorption of drugs (eg, phenobarbital, sulfonamides, and digoxin) and nutrient macromolecules 
(eg, arabinose and xylose) suggest that the processes of both passive and active transport are fully 
mature in infants by approximately four months of age. However, most studies conducted revealed 
that absorption in neonates and infants is slower than that of children and adults [82]. Furthermore, 
the relative smaller absorptive surface area in infants and neonates, and thus fewer receptors and 
transport proteins per square unit intestine, is also likely result in a slower absorption of 
compounds. Current evidence regarding P-glycoprotein expression and other absorptive and efflux 
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transporters is contradictory therefore there may be differences in absorption of drugs in the very 
young. 
Additional research is required to better understand and characterise absorptive sites within the 
paediatric GI tract to enable representative models to be developed. 
 
 Dissolution testing and in vitro in vivo correlation (IVIVC) 
Drug dissolution in the physiological environment of the GI tract is often a rate limiting step in the 
oral drug absorption process. Only dissolved drug can permeate the mucosa at the absorptive sites 
in the GI tract [83]. Hence, both solubility of the drug and its dissolution rate are crucial for the in 
vivo behaviour. To some extent these properties are determined by the physicochemical 
characteristics of the drug itself and in addition, they can be strongly affected by the physiological 
conditions in the gastrointestinal tract [84]. Thus, when the aim is to estimate the in vivo dissolution 
process of a given formulation, it is essential to adequately address the relevant in vivo parameters 
within an in vitro setup. 
5.1. Compendial dissolution approach 
In 1970, the rotating basket system (apparatus 1) became the first apparatus to be incorporated into 
the United States Pharmacopoeia (USP) [85] as a dissolution device for solid oral dosage forms. 
Shortly thereafter the paddle method (apparatus 2) [86] was accepted as the second official 
dissolution method. During the following years, the field of dissolution grew and a number of 
pharmacopoeias adopted additional apparatus and refinements thereof. Currently, dissolution test 
devices for testing solid oral dosage forms are described in various pharmacopoeia, such as the US 
(USP), the European (PhEur), the British (BP) and the Japanese Pharmacopoeia (JP). The largest 
number of official dissolution methods can be found in the USP, which currently describes seven 
different dissolution devices. 
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During the last decades, dissolution testing has evolved as a highly valuable in vitro test to 
characterize drug delivery performance. For a long time, it has been mainly used as a tool for quality 
control and regulatory purposes. Many monographs specifying dissolution conditions for quality 
control of specific drug/formulation combinations can be found in international pharmacopoeia. 
Because of the importance dissolution testing has assumed in the last few decades, various official 
regulations have been published worldwide. For instance, the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) have published several guidance documents that 
provide information and recommendations on the development of dissolution test methodology, set 
dissolution specifications and describe the regulatory applications of dissolution testing. 
Current compendial methodologies used to characterize drug release from oral dosage forms are 
mostly still based on the paddle and basket apparatus in combination with compendial media, i.e. 
simple aqueous buffers. The typical media volume is in the range of 500-1000 mL and where the 
volume is not sufficient for complete drug dissolution, surfactants, such as sodium lauryl sulphate 
(SLS) or Tween 80, are added to provide sink conditions. While such test methods are generally 
useful for quality control, they do not reflect complex human gastrointestinal physiology and, 
particularly for formulations containing poorly soluble drugs, are of limited use when the objective is 
to predict the in vivo performance of a dosage form or to achieve an IVIVC for both adult and 
paediatric formulations. In recent years however, there has been a strong push to identify 
bioavailability problems of a drug formulation based on the results of appropriately designed 
dissolution experiments. 
5.2. BCS dissolution approach  
As indicated in the previous section, the BCS [31] was established as a prognostic tool for estimating 
the in vivo bioequivalence of orally administered formulations. The original purpose of developing 
such a scientific framework was to reduce regulatory burden without compromising the quality of 
drug products. According to official FDA and EMA guidelines [19] [22] in vivo bioequivalence studies 
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may be exempted if an assumption of equivalence of in vivo performance can be justified by 
satisfactory in vitro data. Currently, a BCS-based biowaiver is restricted to highly soluble drug 
substances with known human absorption formulated in solid oral IR formulations. BCS dissolution 
experiments are designed to screen for similar in vitro dissolution of two IR products under 
physiologically relevant experimental pH conditions. In vitro dissolution has to be investigated using 
the basket or the paddle apparatus at 100 or 50 rpm in up to 900 mL of medium within the pH-range 
of 1 – 6.8 (at least pH 1.2, 4.5, and 6.8) [19, 22]. In contrast to the compendial test design, the use of 
surfactants is not allowed. A rapid or very rapid drug release (> 85% within 30 or 15 min) in all three 
pH conditions indicates that no bioavailability issues with the IR formulation should be experienced. 
Nowadays, the BCS dissolution approach is not only used in the regulatory bioequivalence 
assessment but also as a scientific and mechanistic classification tool at almost every stage of drug 
discovery and development [87].  
The main principle of the BCS in vitro dissolution experiments is to determine drug release over the 
entire GI pH range. However, as already discussed for the BCS solubility approach, no additional 
parameters that can affect intraluminal solubility and dissolution of a compound are addressed in 
this in vitro test design. Beyond that, the media volume is high and thus often even not 
representative for the fluid volumes available in the upper GI tract of adults. This is particularly true 
for the fasted state. The dissolution profiles obtained in such conditions hardly can be a surrogate 
for the in vivo performance of these formulations since neither the pH conditions, nor the volume or 
any additional media parameters seem to be appropriate to simulate the intraluminal contents in 
the upper GI tract of children. It is also questionable, if the basket and the paddle run at 100 or 50 
rpm, respectively, can reflect the hydrodynamics, i.e. GI motility and fluid / chyme movement in the 
paediatric GI tract in a meaningful manner. 
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5.3. Biorelevant dissolution approach 
The biorelevant dissolution media shown in Table 4 were developed to reflect the physicochemical 
parameters of intraluminal fluids in the fasted and fed state upper GI tract of an average adult. 
These media were successfully used in establishing in vivo in vitro correlations for oral immediate- 
and modified release (MR) formulations, using simple compendial dissolution equipment, such as 
the paddle, the flow-through cell or the reciprocating cylinder apparatus [83, 88-93]. The application 
of biorelevant media was also successful when the aim was to predict in vivo precipitation of weakly 
basic drugs after gastric dissolution and subsequent emptying into the small intestine [94, 95] using 
a non-compendial transfer model [41, 96]. The latter results indicate that not only in the case of MR 
formulations which typically release the drug along various segments of the GI tract, but also for 
several IR formulations adequate prediction of the in vivo performance is only possible with a 
sophisticated test setups. Particularly for dosage forms containing poorly soluble weak acids and 
bases that may precipitate in the GI lumen, a multi-segment approach as used in the transfer 
experiments can better address the changing GI environment to which drug and dosage form are 
exposed prior to reaching the site of absorption. 
Through the use of modern techniques in monitoring the gastrointestinal transit of oral dosage 
forms, it is known that (i) independent of the nature of the formulation gastrointestinal transport is 
a discontinuous rather than a continuous process; (ii) there is also not necessarily a continuous 
phase of free fluid available in the gut lumen; and (iii) the intraluminal conditions can be strongly 
affected by food intake [97]. Based on these findings, in the last decade, a variety of biorelevant 
dissolution approaches, addressing not only the (changing) media composition and digestion (see 
Table 4), but also the relevant residence times and motility patterns in the human gastrointestinal 
tract, were introduced. Approaches that address conditions in the upper GI tract include for instance 
a biorelevant stress tester to simulate the impact of physiologically-based mechanical stress that 
may occur during the GI passage of a dosage form and also to simulate an intermittent contact of 
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the dosage form with the dissolution medium [98, 99], the dynamic gastric model (DGM) to simulate 
mechanical and enzymatic gastric processing of foods and the impact of digestive processes on the 
dosage form performance [100] and the TIM-1 artificial digestive system, representing a multi-
compartmental, dynamic, computer-controlled gastrointestinal model intended to simulate a range 
of physiological parameters including the secretion of saliva, gastric- and pancreatic juice along with 
digestive enzymes, bile flow, peristalsis for mixing and transport, the changing gastric and intestinal 
pH conditions and the continuous removal of digested lipophilic and hydrophilic compounds [101]. 
With these models, the complex influences of physiological parameters on in vivo dissolution is likely 
to be even better understood and application of such models often provide a good in vivo 
predictivity for the average adult subject. 
5.4. Biorelevant dissolution approach for paediatrics 
The dissolution methods cited in previous sections (5.1-5.3) were developed to better understand 
the impact of different physiological parameters on in vivo drug release [41, 83, 88-96, 98-101]. In 
many cases, application of such physiological based models enabled an IVIVC to be achieved and 
thus, they have established themselves as valuable tools in formulation development. However, 
these approaches address adult physiology rather than simulating physiological conditions in the GI 
tract of children. Therefore, without modification, they will not be applicable to simulate the 
physiological parameters relevant to drug release and absorption in the paediatric population.  
In addition, whilst these biorelevant approaches for the adult population address many details of 
human GI physiology, they are not necessarily applicable to simulate conditions in the oral cavity. 
Since current paediatric drug therapy is dominated by oral liquids, multi particulate dosage forms or 
formulations intended to disintegrate in the oral cavity [102-104], this site is of particular 
importance in paediatric drug therapy.  For the cited, but also for any other oral dosage form, 
contact with saliva can have a huge impact on the overall in vivo performance since it might help to 
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dissolve the drug, yet can also cause precipitation or degradation of the drug or result in unforeseen 
drug release from enteric coated dosage resulting in exposure to the taste buds. To date, a 
biorelevant model simulating all aspects relevant to dissolution in the oral cavity has neither been 
established for adults, nor for children. For assessing the in vitro behaviour of chewable tablets and 
medicated chewing gums in quality control, a mastication apparatus is described in the PhEur [29]. 
For oral lyophilisates and orodispersible tablets, a disintegration test performed in water is regarded 
as an adequate quality control method [29]. For orodispersible films and compressed lozenges the 
Ph.Eur. requests a suitable test to be carried out to demonstrate the appropriate release of the 
active substance(s), but details on how such a test should be performed are not given [29]. In both 
USP [105] and the FDA Dissolution Methods Database [106] dissolution methods for orally 
disintegrating tablets are specified [107]. However, these methods are based on either the paddle or 
the basket apparatus and experiments have to be performed in 500 – 1000 mL of water or simple 
buffer media. Thus, the methods might be useful for QC, but are not suitable for any biorelevant 
approach.  
Over the last years, several alternative methods for screening drug release of orally disintegrating / 
dissolving formulations have been proposed. These range from modified paddle and setups through 
several non-compendial disintegration testers and the texture analyzer through several other non-
compendial devices [107-110]. These methods also use different endpoints such as drug dissolution, 
wetting time, dispersion or disintegration [109]. However, these methods were mainly developed for 
quality control and only partly address the conditions relevant to dissolution in the oral cavity. This is 
particularly true for the media applied in these experiments. In most of the approaches water and 
simple buffer media, sometimes not even representing the physiological pH-range in the oral cavity, 
were utilized. However, a biorelevant test setup would require using a physiologically relevant 
medium based on the physicochemical characteristics of human saliva. Several simulated salivary 
fluids have been proposed in the last decades [111-116] and were recently reviewed by Marques et 
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al. (2011) [117]. The simulated salivas differ in composition but all fluids contain a variety of 
electrolytes and some of them also several of the numerous additional constituents of human saliva, 
mainly represented by enzymes and mucosal glycoproteins. Nevertheless, similar to the all other 
biorelevant fluids discussed in this review, the simulated salivary fluids reported in literature address 
the average saliva composition of adults rather than considering the saliva composition of children 
of different age groups. 
It is clear that a universal approach to dissolution testing to predict in vivo drug release in the 
paediatric GI tract is extremely complex as the physiological aspects relevant to age, dosage form 
and dosing conditions have to be addressed in the test design. 
To date, no concepts for biorelevant dissolution approaches for paediatrics have been presented. 
However, as already discussed in previous sections, there is a clear need in establishing such test 
methods. A BCS-like but biorelevant solubility test approach would represent an adequate base for 
such a dissolution test design, i.e. establishing a set of biorelevant media simulating the 
physicochemical conditions following typical dosing conditions in the upper fasted and fed state GI 
tract of the paediatric population is essential. Moreover, the age-dependent fluid volumes available 
in the GI segments relevant to drug release as well as the residence times in these segments would 
need to be addressed. As indicated before, in recent review articles [3, 4, 44] typical fluid volumes 
available at the relevant sites in the paediatric GI tract were not discussed. Detailed information on 
gastric emptying and intestinal transit times are also lacking and residence times in the oral cavity 
are not discussed. However, even with the little information presented in the cited articles [3, 44], it 
is obvious that gastric emptying and small intestinal transit in newborns and infants are essentially 
different from children, adolescents and adults. As gastric emptying determines the rate at which a 
drug appears at the main site of absorption, this should be one of the key parameters in the 
biorelevant dissolution test design.  
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However, even following characterization of the paediatric GI tract and establishing a set of 
biorelevant media for the different age groups, there are several additional parameters such as 
residence time in the oral cavity, passage times through the different segments in the GI tract and GI 
motility will also need to be addressed to develop a relevant model. Compendial paddle and basket 
equipment are unlikely to be appropriate for this purpose since they cannot be run with the small 
media volume that might particularly be required for simulating GI conditions in the very young 
children. Therefore, the flow through cell is considered to be the best current compendial option. In 
the last few decades, various miniaturized dissolution setups have been introduced and the mini 
paddle [118, 119] also might represent be an alternative to the compendial paddle apparatus. 
Whenever the intention is not to simply screen the impact of media volume and composition but 
also that of additional physiological parameters on drug release, non-compendial (-based) setups 
will be required. In cases where in vivo drug release from oral IR dosage forms in adults is affected 
by several physiological factors, in vitro results obtained with physiologically based dissolution 
methods such as the transfer model, biorelevant stress test apparatus, the Dynamic Gastric Model 
(DGM), or the TIM-1 apparatus typically provide a much higher in vivo predictivity compared to 
results obtained with simple (compendial) test setups. Therefore, physiologically based dissolution 
models should be developed for different paediatric age groups.  
Several formulations like oral films, orally disintegrating tablets or granules, but also oral liquid 
formulations will require a test setup simulating conditions in the oral cavity. As discussed before. 
compendial apparatus are not suitable for this purpose and also the alternative approaches 
presented in the literature cannot be regarded as biorelevant. Therefore, there is a strong need to 
establish adequate dissolution tests addressing these needs. In addition, establishing an orogastric 
transfer model to screen for the impact of residence in the oral cavity on the overall in vivo 
performance of the formulation should be considered. As already discussed for a biorelevant 
paediatric solubility approach, a longer residence in the oral cavity could result in: precipitation of 
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poorly soluble weakly basic drugs; impaired stability of a compound; loss of integrity of enteric 
coatings and consequently affect the bioavailability of a number of compounds and formulations. 
5.5. Developing paediatric biorelevant dissolution testing methods/apparatus 
Currently, biorelevant dissolution tests for the paediatric population are not available. However, 
such test methods represent an essential prerequisite for increasing the safety and efficacy of oral 
paediatric drug formulations. Biorelevant dissolution methods should enable to establish IVIVCs, 
that is, predict the in vivo performance of an oral dosage form based on results obtained in an in 
vitro setup addressing the relevant physiological parameters of children of the different age groups. 
In designing such biorelevant and in vivo predictive dissolution tests for the paediatric population, as 
well as oral and gastrointestinal solubility of orally administered drugs essential information is 
required on the following: (i) the residence times in the oral cavity and the different GI sections, (ii) 
the fluid volumes available at these sites and (iii) the motility pattern and the passage times in the 
paediatric GI tract. Unfortunately, most of these data cannot be obtained from the current 
literature. However, the few physiological data available to date clearly indicate that particularly in 
the very young age groups (newborns, infants and pre-school children) big differences to the adult 
physiology has been reported. As already mentioned for the biorelevant solubility approach, there is 
a strong need to adequately simulate the composition of salivary, gastric and small intestinal fluid in 
both the fasted and the fed state. Thus, for a biorelevant dissolution test design, there is a strong 
need to characterize the paediatric oral cavity and gastrointestinal tract in more detail taking into 
account both typical fasted and the fed state dosing conditions for each of the different age groups. 
Based on this information, and based on the experiences made in the biorelevant characterization of 
adult formulations, it should then be possible to compose age related test setups with sufficient in 
vivo predictivity and which will help to improve the quality of oral paediatric drug therapy. 
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 Metabolism 
First pass metabolic inactivation of drugs can affect the bioavailability of orally administered 
medicines; the intestine and liver are the most significant sites involved in first pass drug 
metabolism. There are many drugs whose oral bioavailability is reduced to half the administered 
dose as a result of first pass metabolism in the intestine and liver [120]. 
It is generally stated that the activity of drug metabolising enzymes is low at birth and reaches adult 
values by early childhood. Children in general have a larger liver size and hepatic blood flow per 
body weight than adults [121], which tends to increase hepatic clearance of chemicals when 
enzymatic activity is similar to that observed in adults. This has consequences in terms of dosage 
adjustment where scaling based on mg/kg is not appropriate. 
The ontogeny of specific metabolic pathways has significant consequences for individual therapeutic 
agents and this needs better understanding when extrapolating adult data into paediatric 
populations. The example of the grey baby syndrome resulting from dosing chloramphenicol to 
neonates at doses extrapolated from adult data is often used to highlight the importance of 
understanding ontogeny of metabolic pathways [16]. This review will summarise existing knowledge 
on metabolic ontogeny with a focus on the intestine and liver as sites of metabolism. For more 
extensive reviews the reader is directed to alternative sources including; ontogeny of drug 
metabolising enzymes [14, 122]; and age related changes in the metabolism of drugs [14, 123-127]. 
This review will limit its focus to neonates up to adulthood with foetal data included as a point of 
reference rather than the focus of the review. 
6.1. Drug metabolism in the gut lumen 
The microflora of the intestinal lumen changes with age; this alteration in bacterial colonization has 
implications in terms of drug metabolism within the gut. This topic has been reviewed for adults 
previously (eg [128, 129]).  
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The greatest changes in colonisation occur in the hours and days immediately following birth. The 
pattern of bacterial colonization within the gut is influenced by feeding with differences observed in 
breast fed compared to formula fed infants [130]. There are known differences in bacterial 
composition based on age and diet [131], these factors may be important in predicting the free 
concentration of active drug within the gut lumen in infants and children. Andrieux et al. (2002) 
compared the faecal microflora from children (3-15 years) to adults and elderly adults to investigate 
levels of bacterial enzymes (-galactoside, -galactoside, -glucoside, -glucuronidase, 
neuraminidase, N-acetylgalactosaminidase, -fucosidase, nitrate reductase and azoreductase). 
There were no significant differences in the enzyme activities between the three populations; 
although the data was more variable for the children [132]. This result is interesting as it suggests 
that luminal metabolism will match adult values from 3 years, however, there is still very limited 
data on infants and neonates. Other sources also agree that intestinal colonisation reaches adult-like 
composition by aged 1-4 years (eg [133-135]). 
The maximum number of operational taxonomic units (OTUs) for children between 0 and 1 year is 
approximately 1000, whereas adults commonly exhibited between 1000 and 2000 OTUs [136]. 
However, interindividual variations are significantly greater among children than among adults: the 
microbiota of children is dominated by a few bacterial genera and species, with Bifidobacterium 
being most prevalent in infants [137].  
The age dependant excretion of digoxin reduction products by inactivation within the gut lumen has 
been shown to increase with age; from 1-3% of infants; 7% of children; 10% of adolescents 
compared to 40% of adults [138]. However, Linday et al. (1987) also reported that the digoxin-
inactivating bacteria (Eubacterium Lentum) were present as early as the second week of life. This 
suggests that it is the metabolic activity of the gut flora that needs to be understood rather than 
simply quantifying the species present. 
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Bile acids and neutral sterols are metabolised extensively within the lumen of the human intestine. 
Huang et al. (1976) compared faecal samples from infants <1.5 years children at 4 years and adults 
to look at metabolic products of bile acids and neutral sterols [135]. Their results suggested that 
metabolism by 7 α-dehyroxylation of bile acids increased significantly with age. Metabolism of 
cholesterol (by bacterial biohydrogenation and subsequent reduction) also increased with age with 
values at 4 years being similar to those found in adults [135]. This data agreed with previous reports 
that 7 α -dehydroxylation bacteria are not established in the gut before 12-18 months [139]. 
Previous studies reported that excretion of methane in breath, as a consequence of specific gut 
microflora, did not occur in children younger than 2 years of age and reached adult values at 10-14 
years [140]. This finding is supported by research conducted by Rutili et al. (1996) showing that 
methanobacteria was not detected in faecal samples from children under 27 months of age; with an 
incidence of 40% at 3 years and 60% at 5 years [141]. 
These data indicate that metabolism within the gut is similar to adults at some point ranging from 12 
months to 14 years. This finding demonstrates the need for additional research in this area to better 
understand bacterial colonisation as well as the impact of diet on luminal metabolism of drugs in 
paediatric populations. 
6.2. Drug metabolism in the gut wall 
Metabolism in the gut lumen and wall can decrease the bioavailability and the pharmacological 
effects of a wide variety of drugs including cyclosporine, nifedipine, midazolam, verapamil [142-145]. 
The mechanisms that underpin these processes have previously been reviewed in adults (eg [128, 
146]).  
It is primarily enzymes that are responsible for metabolism of drugs as they traverse the intestinal 
wall therefore the ontogeny of enzymatic activity can affect the fraction of drug absorbed escaping 
first pass metabolism within the gut wall (Fg). 
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Stahlberg et al. (1988) measured the activity of aryl hydrocarbon hydroxylase; epoxide hydrolase 
and glutathione peroxidase using small intestinal biopsies taken from children. The data showed that 
neither epoxide hydrolase nor glutathione peroxidase showed any change in activity with age [147]. 
However, aryl hydrocarbon hydroxylate showed a significant increase in activity with age with a 
correlation of 0.38 and values for <1year olds being 64 pmol/min/mg protein compared to 185 
pmol/min/mg protein in 11-12 year olds [147]. However, other research has demonstrated that 
epoxide hydrolase activity does change with age as foetal gut activity of epoxide hydrolase was 
twofold higher compared to adults [148].  
 
6.2.1. CYP 3 gene family 
The cytochromes P450 (CYPs) constitute the major enzyme family capable of catalyzing the oxidative 
biotransformation of most drugs and are therefore of particular relevance for clinical pharmacology. 
The CYP3A subfamily is predominant, accounting for approximately 70% of the cytochromes in the 
adult small intestine, and is involved in the metabolism of more than 70% of currently administered 
drugs [149]. 
CYP3A4 and CYP3A5 are abundantly present in the small intestine in adults; yet there is limited data 
regarding their expression in paediatric populations. A study to investigate localisation and 
expression of CYP3A in 59 normal duodenal biopsies from Caucasian children aged 1 month to 18 
years; showed that CYP3A was expressed in all children 6 months and older and in half those up to 6 
months [71]. However, there was a subsequent decline in CYP3A4 and CYP3A5 levels with age from 
1-17 years [71]. A study by Johnson et al. (2001) investigated intestinal expression of CYP 3A with 
age; an increase in CYP3A expression was observed that was mirrored by a corresponding change in 
CYP3A4 enzyme activity [150].  
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6.2.2. GSTA1-1 Expression 
Glutathione S-transferase alpha 1 (GSTA1–1) is the enzyme principally responsible for the 
conjugation of busulfan. Results from intestinal biopsies from children showed that busulfan-GSH 
conjugase activity was 77% greater in intestinal biopsies obtained from children under 5 years 
compared to those from 9-17 years old [151]. 
6.2.3. Sulfotransferases 
Sulfotransferase (SULT) activity has been reported in both adult and foetal intestine; with mean 
activity values more than three times higher in foetal tissues compared to adult [152]. Cappiello et 
al. (1991) measured the activity of SULT isoforms from adult of foetal intestinal tissue samples using 
either p-nitrophenol or dopamine as substrates; their results found higher adult activity (ratio = 2.6) 
for p-nitrophenol substrate mediated activity and lower adult activity (ratio 0.8) for dopamine 
mediated activity [153]. 
6.2.4. Alcohol Dehydrogenases (ADH) 
Using intestinal tissues samples from subjects ranging from 9 weeks gestation to 20 years, the 
expression of ADH was not observed to change appreciably with age [154]. 
6.2.5. Uridine 5'-diphosphate-glucuronosyltransferases (UGTs) 
UGTs are highly expressed in the gastrointestinal tract, where they have the potential to influence 
the pharmacokinetics and biological effects of ingested drugs. However, there is little known about 
the ontogeny of UGT expression in the intestine. 
 
These findings in 6.2.1-6.2.5 demonstrate that gut wall metabolism can vary with age depending on 
expression of specific enzymes at this site and their ontogeny. Further research is required to better 
understand the expression of these compounds as well as their activity with age and how this can 
affect bioavailability of many susceptible drug compounds. 
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6.3. Drug metabolism in the liver 
There is a wealth of literature data on ontogeny of hepatic enzymes; Table 6 presents a summary of 
this data with the reader directed to other sources for more complete reviews  (eg  [14, 155, 156]). 
This table includes information on expression and/or activity of major enzymes although it is 
recognised that these factors are not correlative. Indeed, differences have been observed when 
reporting enzyme expression based on mRNA versus protein quantification versus enzymic activity 
which can lead to different conclusions regarding enzyme ontogeny [157, 158]. 
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Table 6. Summary of expression/activity of hepatic enzymes in paediatric populations as a percentage of adult values 
Enzyme Foetus Neonate Infant Child 
(2-5y) 
Child 
(6-11y) 
Adolescent 
(12-18y) 
Comments Reference 
Human hepatic esterases 10  25     [159] 
P450 family         
CYP 1A2  4-5 
10 
50 
10-25 
50 
 
30-81 
50-55 
 
150 
50-55 - 
 
100 
CYP1A2 activity may be delayed in 
breast fed infants [160] 
[161] 
[162, 163] 
[164] 
[127] 
      100  [165] 
CYP 2A6       100  [165] 
CYP 2B6 0 
present 
 
 
10 
 
   
 
 
Adolescents show reduced values 
compared to adults 
[163] 
[166] 
CYP 2C9  30 100     [124] 
CYP 2C19 12-15    100   [124] 
CYP 2D6  5 
 
30 
100 
70    [167] 
[168] 
CYP 2E1 10-30  100     [169-171] 
CYP 3A4 10  30-40 100    [172] 
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15 
50 
15 
 
30 
 
50 
[173] 
[168] 
CYP 3A7 1200 700 200 100 100 100  [168] 
Alcohol Dehydrogenase 
(ADH) 
  100    A switch occurs from foetal expression 
of ADH1A to adult expression of 
ADH1C 
[15, 154] 
 
Aldo-ketoreductases     75   [174] 
Aldehyde Oxidase  10 100     [175] 
Flavin mono-oxygenases 
(FMOs) 
  Expression 
measured 
 50 
 
100 FMO expression switches from FMO1 
expressed within the foetus to FMO3 
within the adult 
[176] 
Epoxide Hydrolases 25-50       [177, 178] 
Uridine 5’-diphospho-glucuronosyltransferase       
UGT1A1   100 
50 
100   
50 
Adult levels observed at 4 months [179, 
180] 
[181] 
UGT1A4 0 present 100     [179, 
182] 
UGT16A 0 present   100  
50 
Adult levels observed at 14 months [180, 183, 
184] 
[181] 
UGT1A9   45-60 100    [179] 
46 
 
50 [162] 
UGT2B4   40 40    [179] 
UGT2B7 10-20  
10 
100 
15-20 
100 
15-20 
 
50-60 
 
70 
 [179, 
185] 
[186] 
UGT2B17 3 13      [187] 
Sulfotransferases 
(SULT) 
100       [188] 
SULT1A1 100       [188] 
SULT1A3 >100 100      [189, 190] 
SULT1E1 >100 
<25 
      [188, 190] 
[152, 191] 
SULT2A1  100      [188, 190] 
N-acetyltransferases (NAT)      Present in neonates, increasing in 
infants with a reduction in children 
[192] 
NAT1 30   100    [193, 194] 
Thiopurine S-
methyltransferase (TPMT) 
30       [195] 
Glutathione S-transferases (GSTs)        
GSTA1 70 100      [196, 197] 
GSTA2 25 60      [196, 197] 
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GSTM 20 100      [196] 
GSTP1 Present 
at high 
levels 
Present     Undetectable in adult samples [197] 
         
Note that all values are approximations and may refer to % expression or % activity relative to the adult value. 
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Table 6 highlights that the most clinical relevant phase 1 enzymes (CYPs) are generally present at low 
levels in neonates reaching adult values at 1-5 years depending on the isoform. Phase 2 enzymes 
also show a wide age range in reaching adult values; UGT reaching adult values are dependent on 
the isoform; SULT adult values are reached early for all isoforms; NAT is variable in infants and 
reduced in children reaching adult values between 2-5 years; there is limited data on TMPT in 
children.  
Differences in enzyme expression and activity can result in altered oral bioavailability of drugs (eg 
midazolam and zidovudine [198, 199]) or production of metabolites in paediatric populations that 
are not observed in adults (eg caffeine production in neonates receiving theophylline, differences in 
metabolite production in children with valproic acid, paracetamol, chloramphenicol, cimetidine and 
salicylamide [13]).  
Liver blood flow is increased in paediatric populations due to the larger ratio of liver to total body 
mass in infants and young children [121]. This increased blood flow to the liver will increase hepatic 
clearance of drugs. The first pass effect where a drug is cleared on first passage through the liver 
may therefore be greater in paediatric patients although the level of enzymes present will also 
influence this rate. Recently the microsomal protein content within the liver has been reported to 
increase with age from an estimated of 26mg/g in neonates rising to a maximum of 40mg/g in a 30 
year old adult [200].  
 
 
6.4. Future work required to understand paediatric metabolism mechanisms 
The information on ontogeny of metabolic pathways is very limited with patchy coverage of even 
the most important enzyme families (eg CYPs). More data has been reported from foetal samples 
and neonates with very limited information from infants and children. There is more data on liver 
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ontogeny compared to intestine; this may be expected due to the relative contribution of 
metabolism from these two organs. Some enzyme systems develop within the foetus demonstrating 
near adult values at birth (eg sulfotransferases); these cause less concerns, in terms of drug 
performance, compared to those with significant postnatal development and associated variability. 
There are at least two examples where the bioavailability of drugs was increased in children 
compared to adults as a result of differences in metabolism; midazolam and zidovudine.  De Wildt et 
al. (2002) reported that midazolam elimination in preterm infants was approximately 10-fold lower 
than that reported in older children and adults; this reduction followed the pattern of CYP3A4 
ontogeny in both the intestine and liver. A comparison of orally and intravenously administered 
midazolam enabled the authors to conclude that both liver and intestinal metabolic pathways 
contributed to the difference in elimination observed [199].  The oral bioavailability of zidovudine 
was observe to decrease from 89% in neonates under 14 days to 61% in those over 14 days old 
[198]. 
There are several recognised knowledge gaps in this field where additional research is required to 
define the true ontogeny of many enzyme systems. Efforts are required to ensure that future studies 
embrace a wide range of ages rather than relying on small sample sizes with a snapshot of 
expression; also appropriate methodology to ensure that the enzyme activity measurements are 
robust. 
 Paediatric Clinical Testing 
In paediatric drug development several factors need to be considered to justify the decision to 
proceed with a pediatric clinical program for a medicinal product.  These include: the presence of a 
serious or life-threatening disease for which the medicinal product represents a potentially 
important advance in therapy; the novelty of the medicinal product; the existence of unique 
paediatric indication and the need for paediatric formulation.  
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In drug development, bioavailability clinical studies are needed for a novel compound for 
determination of: the best administration route (absolute bioavailability) and/or the best 
formulation (relative bioavailability), whereas bioequivalence studies determine the equivalence of 
formulations for novel/old compounds.  
ICH E11 guidance on clinical investigation of medicinal products in the paediatric population [11] 
provides information on if and/or when pharmacokinetic, bioavailability and bioequivalence studies 
have to be performed to determine pharmacokinetic parameters in the paediatric population, to 
enable dosing recommendations and to support formulation development. 
The FDA Pediatric Study Decision Tree [201], reproduced in Figure 1, provides a simple assumptions-
based framework that can be a helpful starting point in determining the pediatric studies (excluding 
oncology studies) necessary for labeling based on the ability to extrapolate efficacy from adult or 
other data.  
 
 
Option C 
Is there a pharmacodynamics (PD) 
measurement that can be used to predict 
efficacy in children? 
Conduct pharmacokinetic (PK) studies in 
children which are designed to achieve drug 
levels similar to adults and then conduct 
safety trials at the proper dose 
Yes  No  
Is it reasonable to assume exposure 
response (ER) in children when compared to 
adults? 
Is it reasonable to assume that children 
when compared to adults have a similar (a) 
disease progression and (b) response to 
intervention? 
No to either Yes to both 
Yes  No  
Conduct PK/PD studies to establish an ER in 
children for the PD measurement, conduct 
PK studies to achieve target concentrations 
based on ER, and then conduct safety trials 
at the proper dose 
Conduct PK studies to establish dosing and 
then conduct safety and efficacy trials in 
children 
Option B Option A 
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Figure 1: FDA paediatric study decision tree (reproduced based on [201]) 
 
Bridging procedures can be used if disease progression, exposure-response relationships, and clinical 
endpoints are similar in adults and children and in these circumstances, confirmatory efficacy trials 
in children are not necessary [11, 202] and only safety trials have to be conducted. Otherwise 
efficacy trials need to be conducted in the paediatric population due to a lack of any appropriate 
pharmacodynamic measurement (Figure 1) [12, 23, 202]. Safety profiles cannot be transferred 
directly to children even when the disease processes are the same [203]. The regulatory criteria for 
accepting extrapolation and/or modeling as pivotal evidence may take into account factors other 
than the ones mentioned in the decision tree (for example feasibility of trials, ethical constraints, 
and unmet medical need) [204]. The extrapolation of efficacy from adult and other data to the 
pediatric population minimizes the exposure of children to clinical trials; increases the speed and 
efficiency of pediatric drug development and allows pediatric patients timely access to safe and 
effective medicines [201]. The experience of the US FDA in extrapolating efficacy in paediatric drug-
development programs has shown that for 370 paediatric studies submitted to the FDA between 
1998 and 2008, extrapolation of efficacy from adult data occurred for 82.5% and defined as 
complete for 14.5% and partial for 68% of them. When extrapolation was used, 61% of the drug 
products obtained a new paediatric indication or extension into a new age group whereas this 
number decreased to 34% when there was no extrapolation [201]. 
Disease and disease progression models need to be considered when comparing drug response and 
kinetics in adults and children as well as formulation bridging. Disease models can be applied to 
simulate treatment response and in combination with drug models, it is possible to explore the 
implications of different algorithms for dose adjustment [205].  
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The most favorable bridging scenario is when safety and efficacy has already been established in 
adults for the same indication; however an alternative extreme scenario exists when a drug is 
intended only for paediatric indication and prior adult data is very limited. A two-step approach 
starting with an exploratory dose-finding/PK study for primary efficacy, safety objectives and PK 
assessment (ideally to be conducted with the final paediatric formulation) followed by a 
confirmatory efficacy/safety trial (ideally to be conducted with the final paediatric formulation) has 
been suggested for such extreme cases [206, 207].  
 
7.1. Methodology for pharmacokinetic studies 
Following determination that a paediatric pharmacokinetic (PK) study is necessary, the 
methodological approach has to be decided. Some aspects to consider within the PK study design for 
a paediatric population that are described in the relevant regulatory guidelines are presented in 
Figure 2 [11, 208]. 
 
 
Figure 2. Aspects of PK study design to consider within a paediatric population 
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The traditional pharmacokinetic approach (‘data-rich’) in clinical study design involves 
administration of single dose (in case of linear PK) or multiple doses for determination of steady-
state concentration (in case of non-linear PK) of the drug to a relatively small group of subjects with 
relatively frequent blood and sometimes urine sample collection [209]. 
Methodological issues and ethical concerns represent the major obstacles that have limited 
traditional PK approaches in paediatric clinical research. Alternative and innovative approaches to 
clinical trial design in small populations have been developed in the last few decades which are 
referenced in relevant regulatory guidelines [11, 23]. These novel methods go some way to 
overcome the limitations of small sample numbers and of the ethical-acceptability of the trial. A 
variety of alternative designs such as sequential design, adaptive design, bayesian approach, 
randomised withdrawal design, randomised placebo-phase design, three-stage clinical trial design 
have been described for determination of efficacy and safety in the paediatric population [210]. 
The population PK approach (‘data sparse’) method for clinical study design involves infrequent 
sampling (as few as 2-4 samples per subject) of blood from a larger patient population (eg n = 50) 
with analysis via ‘population methodology’ to ensure that the maximum amount of information is 
extracted with minimal disruption to the patients [209]. Recently modeling approaches based on 
physiological based pharmacokinetic (PBPK) modeling, PK/PD modeling have been applied to the 
design of paediatric clinical studies [211]. For example, PK/PD modelling techniques have been 
applied for the improvement of antimicrobial prescribing [212].  
7.1.1. Subjects’ population 
The subjects’ population includes paediatric patients in age ranges in whom the medicinal product is 
likely to be used. A high inter subject variability is expected due to the involvement of patients, yet 
this reflects clinical observation. In some cases variability can be reduced by use of phenotyping of 
patients [11, 208]. 
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7.1.2. Dose 
Estimation of a safe and effective dose in paediatric patients is a challenge. Determination or 
prediction of the paediatric dose–response relationship presents difficulties and additional time is 
required to complete studies in children as compared in adults [213]. Paediatric doses of medicinal 
products have traditionally been scaled from adult doses, using functions related to body weight, 
height, or age. The development of allometric approaches was an advance when compared with the 
use of Clark's Rule and Young's Rule 40 years ago and may have potential clinical utility in children 
older than 8 years of age and in adolescents [214]. But these approaches may be questionable when 
complex absorption and disposition processes are encountered and can fail to predict exposure 
accurately, particularly in paediatric patients younger than 1 year of age in which dramatic age-
related differences in drug disposition are observed [215-217]. A more mechanistic approach 
combining the ADME in adult population with the physiological development in the paediatric 
population should be used for the assessment of the ‘first-in-children’ dose [211].  
7.1.3. Administration route 
Intravenous administration of a true solution or a very fine emulsion or dispersion of the active 
ingredients in adequate and non-toxic solvent is suggested for new compounds. In case that the 
intravenous administration is not possible, then the formulation should be administered either by 
the oral route or by an adequately justified other chosen route [11]. 
7.1.4. Formulation 
A relative bioavailability study is required for new formulations introduced as highlighted previously 
in Section 7 (Paediatric clinical development) [11]. 
7.1.5. Blood Sampling 
Minimal blood volume sampling coupled with sensitive assays are required for clinical studies in the 
paediatric population. Technological advances that allow accurate assays with smaller sample sizes 
and alternative sampling strategies (eg, dried blood spots or saliva samples) are of great importance 
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for paediatric clinical studies [209]. Population-based pharmacokinetic methodologies offer 
advantages in sampling, as less frequent sampling than in traditional pharmacokinetic studies is 
endorsed [209, 218]. 
7.2. Bioequivalence studies 
A change from the formulation used in the confirmatory trials requires a bioequivalence study. 
Bioequivalence studies for paediatric formulations can be performed in adults given that there are 
no differences in metabolism in the paediatric population, and the administration of two or more 
formulations to adults is suggested in order to increase sensitivity.  
However, official FDA and EMA guidelines [19] [22] state that in vivo bioequivalence studies may be 
exempted if an assumption of equivalence in in vivo performance can be justified by satisfactory in 
vitro data. Currently, a BCS-based biowaiver is restricted to highly soluble drug substances with 
known human absorption formulated in solid oral IR formulations. 
 
7.3. Paediatric Labelling 
In response to paediatric legislative initiatives a new paediatric labeling information database has 
been developed from FDA, in which key paediatric information from the studies submitted are 
highlighted and examples of negative paediatric trials are included [6]. In a recent presentation Dr 
Reigner shared that according to the FDA database 33% of paediatric trials were negative until 2011 
revealing a need to increase the success rates of paediatric trials [219]. In the same presentation it 
was noted that, according to the FDA, the biggest obstacle to efficient trials relates to poor design 
and planning (poor selection of dose range, poor selection of endpoints, high placebo response rates 
[220], responders vs non/poor responders) and absence of learning from prior trials [219]. 
Recently the FDA initiated a review for aspects of paediatric studies and changes in product labelling 
resulting from Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act 
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(PREA) and their predecessor policies, as well as for assessment of the incentives for paediatric 
studies of biologics [221]. Better information about the efficacy, safety, and appropriate prescribing 
of drugs provided to clinicians, recommendations against a product’s use in children due to 
unexpected harm and development of new formulations were identified after the application of the 
Acts. 
 In silico modelling of clinical data 
Regulatory requirements make the application of model-based approaches an essential step in 
paediatric drug development and can be used as decision tools, as study optimisation tools and as 
data analysis tools [205]. Modelling and simulation techniques can be used to optimize trial designs, 
to characterize and predict pharmacokinetic-pharmacodynamic (PK-PD), to select dose level and 
dosing regimens, to develop sampling schemes, and to select outcome measures. These applications 
are usually based on adult data and the use of extrapolation approaches that incorporate PK and PD 
data from preclinical species, in vitro experiments, and paediatric data from pilot studies or studies 
in older paediatric groups can be included [164, 211]. Modelling approaches have led to a reduction 
and replacement of animal studies during drug discovery and development [205]; the same 
principles can be applied to refine and replace paediatric clinical testing. 
8.1. PK-PD models 
Two modelling approaches can be used. The “bottom–up” approach brings together all the 
information at a subsystem level and the structure of the whole system is identified, whereas the 
“top–down” approach starts from an observable and clinically relevant behaviour and the biological 
components that cause this behaviour are identified [205]. For the “bottom-up” approach, 
integration of age-dependent mechanistic models of drug ADME is possible using a whole-body 
physiologically based pharmacokinetic (PBPK) model, but further research is needed for their 
development [222]. 
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PK-PD relationships are believed to be similar in adult and most paediatric populations. However, 
age-related PD differences are rarely reported in the literature, and one of the few examples is the 
increased sensitivity to d-tubocurarine (an antagonist of nicotinic neuromuscular acetylcholine 
receptors) in neonates and infants compared with children and adults [223]. PD measurements are 
non-invasive, and specific devices exist for measuring various pharmacodynamic measures in 
children, for example: body temperature, heart rate, blood pressure, visual analogue scale for pain, 
EEG, scales for depression, seizure counts, respiratory peak flow, bone density [224]. The use of each 
PD endpoint has to be validated for use in children. An example is the development of an 
observational scale for the measurement of pain in young children, since they are not able to report 
their pain using a visual analogue scale. Following validation such a scale can be used as a PD 
endpoint for the development of PD models for pain in children of different ages [223]. Placebo and 
PD models that link efficacy in children with drug concentrations from adults have been developed 
to minimize the need for paediatric PK or PD studies [225]. PD models can also be linked to indirect 
models where the drug kinetics is described by a single compartment involving a single rate constant 
(referred as ‘kinetic’ models) [224, 226]. Applications of population approaches in paediatrics could 
be extended by further development of PK-PD models. [224]  
PK-PD modelling can be used to generate virtual clinical study outcomes via clinical trial simulation 
(CTS) [227]. A virtual clinical trial is generated based on a PK-PD model; a disease progress (for 
chronic diseases) or placebo-effect model and trial subject demographic covariates [227]. Several 
examples of paediatric CTSs have been published (eg [228-230]). For example, Jadhav et al. (2009) 
[230] showed that use of clinical trial simulations with prior knowledge from adult patients and 
paediatric data from other trial of drug with similar indication could assist in the development of 
anti-hypertensive agents [230]. The lack of knowledge about the mechanisms underlying treatment 
response in many therapeutic indications has prevented the development of mechanistic PK-PD 
models, and most examples often refer to standard statistical models that do not allow for 
inferences about age-related differences in PK [205]. 
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As noted previously, modelling and simulations can be used for determination of an appropriate 
dose in children. Examples based on a PK criterion only (to estimate the paediatric dose that will 
achieve the same exposure as in adults) have been undertaken for asparaginase and montelukast 
[231, 232] and on a PK-PD criterion (achieve a given value of a surrogate marker of efficacy) for 
acyclovir [233]).  
Based on a recent review of the Paediatric Investigation Plans (PIP) from EMA [204], it was shown 
that models are mainly used to compare concentration response between age groups to inform dose 
finding but not to define an extrapolation strategy. This could be attributed to the fact that when 
designing the PIP there is insufficient PK-PD data from the product in the paediatric population to 
enable model building for robust and sensitive PK-PD comparisons.  
8.2. Population models 
Population approaches are now established as the method of choice for analysing data collected in 
paediatric PK and PK-PD studies in order to get maximum information from the limited data 
collected in paediatric studies and to allow the exploration of model-based dosing recommendations 
[209, 211]. Advantages include the ability to analyse studies with sparse and unbalanced PK data 
collection, and the ethically acceptable wide range of clinically relevant covariates [209, 234, 235]. 
The population design (i.e. total number of subjects, number of groups, number of individuals per 
group, dosing and sampling schedules) should be chosen carefully before performing a prospective 
analysis by a parametric method. Optimal design theory that leads to true optimization of the 
design, or stochastic simulations that allow evaluation of a given design planning are used in the 
design of population studies [224]. For the paediatric population, the population model must include 
covariates such as bodyweight and age [224]. Size adjustments are based on allometric or empiric 
approaches, where the allometric approach is more mechanistically and physiologically based [235].  
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8.3. PBPK models 
Mechanistic whole body PBPK modelling can be used in clinical development to (i) predict 
plasma/tissue PK; (ii) to provide a mechanistic understanding of the ADME properties of the drug; 
(iii) to develop PK/PD relationships based on target concentrations and to extrapolate between 
species, dose, route of administration and formulations [236] [224]. Their advantages over empirical 
includes the incorporation of compound-related information and compound-independent 
anatomical and physiological information [211, 237]. The events that take place in each organ, tissue 
or group of tissues are described mathematically using the tissue size, vascular perfusion, 
permeability of tissue membranes to the drug, binding or partition of the drug between components 
in blood or tissue, as well as elimination processes [238]. 
PBPK modelling can be advantageous for the prediction of drug behaviour in paediatric age groups, 
as known maturation processes can be integrated. Physiological parameter values for all ages and 
corresponding regression equations can also be incorporated [224]. PBPK paediatric models 
developed until now are mainly based on prediction after intravenous drug administration [164, 
239-241]. There is a need for further research for development of appropriate PBPK paediatric 
models following oral administration. The need for better absorption models in the adult population 
has previously been highlighted [242], and the developmental changes of the gastrointestinal tract in 
the paediatric population for the PBPK models of oral absorption in paediatrics are an added 
complicating factor [70].  
 
8.3.1. Building paediatric PBPK models 
In order to build a successful PBPK model all developmental changes affecting drug absorption, 
distribution, metabolism, and elimination (ADME) need to be incorporated. A common approach in 
developing a paediatric PBPK model is to modify a PBPK model that has been validated with adult PK 
data and then to incorporate the differences in growth and maturation [243].  
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An age related absorption model should account for the factors contributing to developmental 
changes within the GI tract [82]. Physiological absorption models have been developed for some 
animals and adults [244] [245] [246]. Features of the absorption models in integrated PBPK modeling 
software (eg GastroPlus®, PK-Sim®, Simcyp®) include: pH-solubility and pH-logD profiles; drug 
solubility in biorelevant media; drug dissolution as a function of pH; particle size; diffusivity; particle 
density; ability to handle controlled release formulation using the Weibull equation or an empirical 
in vitro profile; chemical degradation; transit along the gastrointestinal tract;  absorption as a 
function of surface area and effective permeability estimated either by in silico predictions, 
mechanistic equations or by conversion from in vitro permeability measurements; enterohepatic 
cycling; saturable gut and liver metabolism; saturable carrier-mediated transport in the gut by influx 
and efflux proteins [247]. Absorption models developed for the adult population are usually 
combined with in vitro biorelevant dissolution data for prediction of the performance of oral 
formulations [88, 248]. It should be noted that to date there are no reported validated models and in 
vitro biorelevant dissolution methods appropriate for use in children to predict drug absorption as a 
function of age. 
For the distribution model, prediction of distribution volume as a function of age is estimated using 
allometry. The drawback of this method is that the interaction of the drug and the paediatric 
physiology is not taken into account. The use of organ: plasma partition coefficients could provide a 
mechanistic assessment of the dependence of distribution volume on drug and organism-specific 
parameters.  
For the elimination model several approaches have been proposed: (i) scaling total clearance by 
allometry [249] when only size differences exist and should only be used alone when the age range 
of the participants is greater than the age at which the primary pathway of clearance reaches similar 
activity to adults; (ii) adult–child clearance scaling [250] based on the knowledge of the pathways of 
clearance and the ontogeny of those pathways; and (iii) in vitro–in vivo extrapolation in children for 
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prediction of clearance due to intestinal and hepatic metabolism [239]. Knowledge of the pathways 
of clearance and the ontogeny of those pathways are needed for (ii) and (iii). Empirical methods 
linked with allometry are used for the prediction of renal clearance, but in this case active transport 
processes are not included [250]. To date, mechanistic approaches for the prediction of paediatric 
clearance via the kidneys are not available.  
 
8.3.2. Use of paediatric PBPK models 
PBPK modelling is used in paediatric drug development for: selection and optimization of dosing 
schedule and sampling times; simulation-based trial design for virtual populations; risk assessment 
related to drug–drug interactions and target organ toxicities and PK–safety assessment [204, 211, 
243, 251, 252]. 
Optimization of the paediatric age-specific dose and paediatric clinical trials can be performed 
through a learn-and-confirm approach using a minimal number of PK studies in any age group and 
reassessment with a PBPK model [253]. The use of the PBPK model for the estimation of dose is 
mainly “exploratory,” and validation with prospectively collected data is needed in order to become 
“confirmatory”. Furthermore, sampling times can be suggested based on simulations by a PBPK 
model [254]. PBPK models can also be used to address complex clinical drug-drug interactions and to 
explore “what if” scenarios [251]. PBPK models can be linked with PD models for the prediction of 
drug effects in case that child-specific disease outcomes are available and used along with the 
developmental changes [211]. 
Modelling and simulation has the potential to enable paediatric clinical bridging and increase success 
rates. The FDA vision is that design of paediatric studies will be performed 100% by simulation in the 
future [219, 230]. 
 
62 
 
 Paediatric Formulations  
Lack of age-appropriate medicines for children is a global problem, which significantly affects 
developing countries. Furthermore, off-label use of drugs (prescribing outside the terms indicated in 
the product license) in the paediatric population ranges from 60 to 90% with the highest percentage 
being in infants (<1 year of age), indicating that drug treatment in children is still driven by 
empiricism [205, 217]. 
In response to these challenges, the WHO launched its ‘Make Medicines Child Size’ program in 
December 2007, and guidelines for the development of medicines for paediatric use have been 
issued from the regulators [255]. An ideal dosage form for paediatric patients of all ages should 
allow both safe and accurate dose administration [256, 257]. Development of medicines for the 
paediatric population is mandatory for sponsors, with a difference on the time required in US and 
EU: the Pediatric Research Equity Act in US is required at the time of filing the New Drug Application 
whereas in EU the paediatric investigation plan is required prior to filing the Marketing Authorization 
Application [258] [259, 260]. Bioequivalence of the paediatric formulation to the adult formulation, 
is desirable but not required.  
A lot of interest has arisen for new approaches to paediatric formulations development and new 
methods of drug delivery in paediatrics. There may be no single formulation that is ideal for 
paediatric patients of all ages and a range of dosage forms may be required to cover all age groups. 
The development and selection of an age appropriate formulation is related to several factors: (i) 
sufficient bioavailability; (ii) minimal dosage frequency; (iii) minimal impact on the life style of the 
child; (iv) non-toxic excipients in the formulation; (v) convenient and reliable administration; (vi) 
stability; (vii) ease of the production process and (viii) cost of the formulation [82] 
The magnitude of doses required through childhood can vary 100-fold, thus, if a medicinal product is 
to be used in all age groups, theoretically, a range of different dosage forms should be available 
providing different strengths or concentrations to allow simple, accurate and safe dosing [257]. 
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Consequently, a variety of different oral dosage forms, such as solutions, syrups, suspensions, 
powders, granules, effervescent tablets, orodispersible tablets, chewable tablets and gums, mini 
tablets, innovative granules, conventional immediate release and modified release tablets and 
capsules could be available for children of all age categories. However, since safe and effective oral 
drug therapy requires patient compliance, the availability of a broad spectrum of formulations is 
sometimes not enough and palatability is another important parameter to consider in oral paediatric 
drug therapy. To improve palatability, before oral application, dosage forms are often diluted with 
beverages (eg fruit juice or milk) or dispersed in fluids or semisolid meals to mask their taste. Based 
on these considerations, it can be summarized that both the variety of dosage forms required in oral 
paediatric drug therapy and the dosing conditions are essentially different to oral drug therapy in 
adults. 
 
EMA has proposed draft guidance that indicates preferred formulations as a function of the age, 
based on a matrix that combines different age groups and conventional dosage forms. It is important 
to note that this guide reflects some general aspects of acceptability of various dosage forms as it is 
not an in-depth, evidence-based guide, but is based on a questionnaire for hospital paediatricians, 
pharmaceutical scientists and parents [24]. Recent data from South Africa suggest that there is no 
significant difference in refusal rates of children receiving liquid and solid formulations [104]. 
During formulation development, solubility and stability data are useful initial parameters. Solubility 
can determine the potential for a solution formulation. The required solubility is such that the upper 
dose is soluble in a convenient volume; a volume of ≤10 mL was proposed by Strickley (2008) [102]. 
Table 7 summarises a range of oral paediatric formulations with considerations regarding their use 
and limitations.  
Table 7. Oral paediatric formulations: considerations and limitations of use [24, 104, 221] 
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Formulation Considerations/comments 
Oral solutions/ 
Oral 
suspensions 
Easy administration and wide range for dose adaptation 
Appropriate for all age groups 
Limited availability of safe excipients  
Physico-chemical characteristics of the suspension 
Dosing: use of measuring device required for dose accuracy; issues with re-
suspension when sedimentation occurs 
Palatability issues 
Powders/ 
Granules 
Appropriate for all age groups when manipulated to form a liquid 
Appropriate from 6 months when administered as solid, or co-administered 
with semi-solid food  
Dosing: use of measuring device required if not in a sachet  
Issues with aspiration, choking 
Tablets Size and shape may affect acceptability 
Small sizes available (mini-tablets; 3mm) 
Different strengths for children of different ages will be required 
Acceptability can be improved with training in tablet swallowing 
Capsules Can be administered intact (size and shape should be considered) 
Can be opened when justified (co-administration with food, liquids) 
Size and shape may affect acceptability 
Different strengths for children of different ages will be required 
Orodispersible 
tablets 
Issues with direct swallowing, not dispersed in liquid prior to 
administration, choking 
Poor drug load resulting in large unit forms 
Palatability issues 
Chewable 
tablets 
Issues with direct swallowing, chocking 
Palatability issues 
Effervescent 
formulations 
Need to be dissolved or dispersed in liquid prior to administration 
Palatability issues 
Bicarbonate may lead to gastrointestinal malfunctions 
Oral film strips Film area and height limits drug load to 15–25 mg  
Oromucosal 
formulations 
Requires use of applicator 
Requires adhesive properties for retention within the oral cavity 
Issues with swallowing 
 
Use of liquid dosage forms in some developing countries has limitations associated with long-term 
storage or transport under the conditions of extreme temperatures [261]; flexible solid dosage 
forms such as multi-particulates (for example, granules and pellets) can be advantageous in these 
circumstances. Swallowing issues associated with solid dosage forms can be solved by crushing 
tablets or opening capsules and adding the resulting powder to beverages or soft food [104]. Mixing 
with foods or drinks should be explained and justified. Different foods or drinks may have different 
properties and differ in their effect on the medicinal product and may affect product performance 
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and drug pharmacokinetics [24]. For example 6-mercaptopurine is completely degraded within 
minutes by milk or milk products, administration of crushed isoniazid tablets with apple sauce may 
be associated with impaired gastrointestinal absorption and treatment failure [104, 262]. 
 
9.1. “Enabling” formulations 
Preliminary “enabling” formulations might be used in early paediatric clinical trials, as the 
development of paediatric formulations with optimized properties is often a challenging, time and 
resource intensive process [206]. A simple formulation, such as the dispersion of available 
granulates/powder mixes (or the marketed adult formulation) with a liquid vehicle can be used as 
“enabling” formulation.  
Formulation bridging is independent to clinical bridging. In cases where an “enabling” or other 
formulation is used that is not the final paediatric formulation, formulation bridging needs to be 
managed either by a clinical study or by reference to BCS-based biowaivers [263]. If an “enabling” 
formulation is used for the exploratory dose finding study, then two relative BA studies are needed: 
one study with the reference adult formulation (before the first study in children) and one study 
with the final marketed paediatric formulation. Formulation bridging studies are performed in adults 
unless: the drug is unsafe in healthy volunteers; the PK of the compound is different in patients (but 
if the impact of the disease on PK is expected to be similar in both test and reference formulation 
then a relative BA in healthy volunteers is conducted); the PK of the compound is different in 
children (but if the effect on PK is expected to be of the same extent with both formulations a 
relative BA in adult population is conducted) [206]. For paediatric formulations of drugs with linear 
elimination PK that are similar to the adult formulation and differ only in the dosage strength 
similarity can be shown with in vitro dissolution studies [264] [206]. 
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Biopharmaceutic risk associated with formulation changes also involves the BCS classification 
(permeability and solubility) of the drug, taste properties, stability, dissolution rate-limiting effects, 
dosage forms for various age groups with dosing instructions, and variability of PK parameters [263]. 
 
9.2. Excipients used in paediatric formulations 
Excipients are substances added to confer a suitable consistency or form to a drug and are usually 
considered to be inert that is, not affecting the intended action of the therapeutically active 
ingredients [265]. They can be added as diluents, wetting agents, solvents, fillers, binders, 
emulsifiers, absorption enhancers, sustained release matrices, preservatives, sweeteners, stabilising, 
colouring or flavouring agents. In 1937 deaths of more than 30 children from “Elixir Sulfanilamide” 
were reported when the manufacturer tried to create a suitable formulation for young children and 
others who could not swallow pills and included diethylene glycol (a toxic substance found in 
antifreeze) in the formulation [221]. In 1985 the Committee on Drugs recommended that the FDA to 
mandate labelling of over-the-counter and prescription formulations to include a qualitative list of 
inactive ingredients due to adverse reactions reports associated with pharmaceutical excipients 
[265]. Issues related to excipients used in oral paediatric formulations are presented in Table 8. 
 
Table 8. Issues related to excipients used for oral formulations relevant to paediatric patients. [257, 
265] [266] [104, 267] 
Excipient Use Characteristics Toxicity Recommendations 
regarding usage 
Aspartame Sweetener 
(artificial) 
dipeptide of 
aspartic acid and 
a methyl ester of 
rare hypersensitivity 
reactions 
not in homozygous 
autosomal recessive 
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chewable 
tablets, sugar-
free 
formulations 
phenylalanine cross-reactivity with 
sulfonamides. 
phenylketonuria patients 
in patients without dietary 
restrictions <5 mg/kg/d 
Labelling is required for 
prescription and non-
prescription products for 
phenylalanine content. 
Benzyl 
Alcohol 
Preservatives 
injectable 
medicinal 
products and 
solutions 
 Gasping syndrome: 
accumulation of 
metabolites in blood 
(metabolic acidosis) 
and brain 
(neurotoxicity) 
neonates: not be given due 
to their immature 
metabolismup to three 
years old: should be 
carefully evaluated and may 
best be avoided 
Dyes 
 
Colouring 
agents 
azo dyes (sunset 
yellow), quinoline 
dyes (quinoline 
yellow), 
triphenylmethane 
dyes (FD&C blue), 
xanthene dyes 
(erytrhosine) 
gastrointestinal 
intolerance, abdominal 
pain, vomiting, and 
indigestion 
hypersensitivity 
avoid unless necessary 
Ethanol Solvent, 
preservative in 
oral liquid 
preparations 
rapidly absorbed 
from the GI tract 
and metabolised 
to acetaldehyde, 
which is then 
acute intoxication with 
accidental overdose 
and chronic toxicity 
associated with routine 
use for chronic medical 
co-administration of ethanol 
may alter drug absorption 
or metabolism of drugs and 
may result in drug 
interaction 
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oxidised to 
acetate 
PK in preterm and 
term infants not 
well understood 
conditions 
CNS depressant, 
respiratory/ 
cardiovascular 
toxicities at high 
concentrations 
long-term effects of 
low ethanol doses 
under discussion 
max amount in OTC 
medicines (USA):  
0.5% v/v for <6 years of age 
5% v/v for 6–12 years of age 
10% v/v for >12 years of 
age. 
 
Fructose Sweetener  an elevation in blood 
glucose concentration  
laxative effects at high 
oral doses 
Not in patients with 
diabetes, hypoglycaemia, 
hereditary fructose 
intolerance 
Lactose 
(milk sugar)  
Filler, diluent in 
tablets, 
capsules and to 
give bulk to 
powders 
disaccharide of 
glucose and 
galactose 
severe prolonged 
diarrhoea, 
dehydration, metabolic 
acidosis in lactose 
intolerance  
intake of <3g may provoke 
the described symptoms 
sensitivity to lactose varies 
in severity  
Methacrylic 
acid/ethylac
rylate 
copolymer 
Coating 
Materials 
high-strength 
coated 
pancreatic 
enzyme 
formulation 
 fibrosing colonopathy  
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Propylene 
glycol (PG) 
Solvent, 
solubilizer 
metabolised to 
lactic and pyruvic 
acid, excreted 
unchanged in 
urine; 
accumulation of 
PG. in neonates 
t1/2: 16.9 hr 
(adults t1/2: 5hr). 
neurotoxic effects in 
adolescents and 
school-children;in low-
weight newborns and 
pre-term babies 
numerous deaths, 
severe brain damage 
and life-long 
handicaps; metabolic 
acidosis; 
hyperosmolality that 
may cause laxative 
effect 
Up to 25 mg/kg/day in 
adults 
acceptable limit in neonates 
unknown 
Products with high levels of 
PG not to be administered 
<4 years (limited metabolic 
pathway- alcohol 
dehydrogenase).  
not in paediatric dialysis 
patients 
 
Propyl-
parabens 
Preservative agonistic activity 
at hormone 
receptors 
 Up to 5 mg/kg/day for 
children > 2 years with 
mature metabolic capacity. 
recently deleted from the 
list of permitted food 
additives in the EU 
Saccharin Sweetener 
(artificial)  
in solid and 
liquid oral 
dosage forms 
  not included in drug labeling 
Sorbitol Diluent in metabolised to absorbed from GI tract no available 
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tablets, 
plasticiser for 
gelatine in 
capsules, 
vehicle and 
stabiliser in oral 
liquid 
formulations 
fructose and 
glucose 
more slowly than 
sucrose 
recommendation infants 
and children; <20 g/day in 
adults 
contraindicated in 
paediatric patients with 
hereditary fructose 
intolerance and 
hypoglycaemia 
Sucrose 
disaccharide 
Sweetener Converted to 
fructose and 
glucose 
decrease in dental 
plaque pH, dissolving 
tooth enamel and 
promoting dental 
caries 
avoided for paediatric 
patients with hereditary 
fructose intolerance, 
diabetes; for long-term 
therapy large amounts of 
sucrose replaced by sugar-
free formulations 
Sulfites antioxidants  primary exposure in 
children is through 
foods, serious 
reactions have also 
occurred after oral, 
administration of 
sulfite-containing 
drugs 
 
*The American Academy of Pediatrics recommended removal of ethanol from more than 700 liquid 
preparations for children in 1984. This recommendation seems to have been adopted by many 
manufacturers in the USA; the commonly used oral medicines including furosemide listed no ethanol 
as an excipient, unlike in the UK. 
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For adult products, excipient levels are based on the stated amount in an FDA database called 
“Inactive Ingredients Guide” (IIG) and in the case that the excipient doesn’t have a history of prior 
use, safety tests are needed. For paediatric products, no such IIG database exists, and selection of an 
excipient for paediatric formulations is difficult [261]. A single comprehensive and readily accessible 
database of safety and toxicity of excipients for paediatrics (STEP) is under development [268]. 
Significant exposure of infants to potentially harmful excipients (eg ethanol) is common [269]. Safety 
of excipients needs to be determined in paediatric patients and especially in infants whose 
metabolic and elimination pathways may not be fully developed or who may be more susceptible to 
adverse effects during the first few weeks and months after birth [265] [266].  
Recently the EMA has published a concept paper on the need for revision of the guideline on 
excipients in the label and package leaflet of medicinal products for human use (CPMP/463/00) in 
order to include safety concerns regarding excipients that have been identified which are not 
currently addressed in the guideline and the need to cover the paediatric population is noted [270]. 
 Conclusions 
Paediatric biopharmaceutics is crucial in optimisation of the design and development of age-
appropriate oral medicines.  
Successful biopharmaceutic tools for paediatric populations require reliable clinical experimental 
data coupled with mechanistic understanding of all ADME processes. With specific research required 
on: ontogeny of various biological components; maturation of biliary excretion of drugs; metabolic 
capacity of gastrointestinal tract; carrier mechanisms; drug transporters in the gastrointestinal tract; 
first-pass metabolism; protein binding capacity of a drug in children and age-related changes in PD 
[217] [251]. Until such data is available existing biopharmaceutical measurements rely on allometric 
scaling of adult values which is of limited and as yet unknown value. The barriers to clinical research 
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in paediatric patients (or healthy volunteers) need to be carefully considered to ensure that the 
ethical  concerns surrounding safe and effective medicines for all paediatric patients is balanced with 
the ethics associated with involvement of children in clinical trials.  The most vulnerable paediatric 
group are neonates and infants below 6 months as these individuals are most different to adults and 
where predictivity from adult parameters is least robust. Research needs to be prioritised for this 
youngest, most at risk, population. Greater access to existing paediatric clinical data would be useful 
in the validation of new age-appropriate tools that will be developed specifically to understand the 
biopharmaceutics processes in children. 
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